

CURRICULUM VITAE

Revised Sep 7 2022

Dok Hyun Yoon, M.D., Ph.D

Associate professor
Department of Oncology
Asan Medical Center
University of Ulsan College of Medicine
Seoul, Korea

Address (Work)

Department of Oncology
Asan Medical Center
88, Olympic-ro 43-gil, Songpa-gu
Seoul 05505 Korea
Tel: 82-2-3010-5940, 3010-3210
Fax: 82-2-3010-6961
e-mail: dhyoon@amc.seoul.kr

Education

1991. 3 – 1996. 2	Bachelor of Science Department of Life Science Pohang University of Science and Technology Pohang, Korea
1996.3 – 1998.2	Master of Science Developmental Genetics Department of Life Science, Postgraduate School Pohang University of Science and Technology Pohang, Korea
1999. 3 – 2003. 2	M.D College of Medicine Yonsei University Seoul, Korea
2010. 3 – 2012. 2	Ph.D. of Medicine Postgraduate School University of Ulsan College of Medicine Seoul, Korea

Graduate Training

2003. 3 – 2004.2 Internship
Severance Hospital, Yonsei University
Seoul, Korea
- 2005.3 – 2009. 2 Residency, Internal Medicine
Asan Medical Center
University of Ulsan College of Medicine
Seoul, Korea
- 2009.3 – 2011.2 Clinical Fellowship, Oncology
Asan Medical Center
University of Ulsan College of Medicine
Seoul, Korea

Professional Experience

- 1998.3 – 1999.2 Researcher
Laboratory of Drug Delivery System
Korea Institute of Science and Technology
Seoul, Korea
- 2011.3 – 2013.8 Full-time Clinical Instructor
Department of Oncology
Asan Medical Center
University of Ulsan College of Medicine
Seoul, Korea
- 2013.9 – 2018.8 Assistant professor
Department of Oncology
Asan Medical Center
University of Ulsan College of Medicine
Seoul, Korea
- 2017.3 – 2018.8 Research Specialist
Pediatric Hematology, Oncology and Blood Marrow
Transplantation Program
University of Minnesota
Minneapolis, MN, USA
- 2018.5 – 2018.5 Observership
Cellular Therapeutics Center
Memorial Sloan Kettering Cancer Center
New York, NY, USA

- 2018.9 – Present Associate Professor
Division of Oncology/Hematology
Department of Internal Medicine
Asan Medical Center
University of Ulsan College of Medicine
Seoul, Korea
- 2022.4 – Present Director
CAR T-cell therapy center
Asan Medical Center

Certification

- 2009 Diploma, Korean Board of Internal Medicine (#11669)
2011 Diploma, Hematology/Oncology, Korean Board of Internal Medicine
(#6-11-404)

License

- 2003 Korean Medical License (#78813)

Honor

- 2010 Young investigator award
The 9th International Conference of the Asian Clinical Oncology Society
(9th ACOS) held in Gifu, Japan.
- 2010 Travel grant
The 35th European Society of Medical Oncology (ESMO) Congress
held in Milan, Italy
- 2012 Merit award
The 10th International Conference of the Asian Clinical Oncology Society
(10th ACOS) held in Seoul, Korea
- 2012 Travel award
The 10th Annual Meeting of Japanese Society of Medical Oncology
(10th JSMO) held in Osaka, Japan
- 2013 Outstanding investigator award
The 7th Methodology Workshop by Korean Cancer Study Group (KCSG)

Affiliation

- Member, Korean Medical Association
Member, Korean Society of Internal Medicine

Member, Korean Cancer Study Group
Member, Korean Cancer Association
Member, Korean Society of Hematology
Member, Korean Association for Clinical Oncology

Publications in Peer-reviewed Journals:

1. [Clinical Outcomes and Effectiveness of Heart Transplantation in Patients With Systemic Light-chain Cardiac Amyloidosis.](#)
Jeong H, Hwang I, Kim JH, Cho H, Kim MS, Lee SE, Choi HI, Jung SH, Lee JW, Yun TJ, Park JJ, Kim M, Go H, Park CS, Yoon DH, Kim JJ.
Transplantation. 2022 Jun 16. doi: 10.1097/TP.0000000000004230. Online ahead of print.
PMID: 35706094
2. [Improved Efficacy of Tafasitamab plus Lenalidomide versus Systemic Therapies for Relapsed/Refractory DLBCL: RE-MIND2, an Observational Retrospective Matched Cohort Study.](#)
Nowakowski GS, Yoon DH, Peters A, Mondello P, Joffe E, Fleury I, Greil R, Ku M, Marks R, Kim K, Zinzani PL, Trotman J, Huang D, Walzl EE, Winderlich M, Kurukulasuriya NC, Ambarkhane S, Hess G, Salles G.
Clin Cancer Res. 2022 Jun 8:OF1-OF15. doi: 10.1158/1078-0432.CCR-21-3648. Online ahead of print.
PMID: 35674661
3. [Correction to: Relapse with plasmacytoma after upfront autologous stem cell transplantation in multiple myeloma.](#)
Chu TH, Jung SH, Kim K, Lee JH, Mun YC, Bang SM, Yoon DH, Lee HS, Min CK, Lee JJ.
Ann Hematol. 2022 Jul;101(7):1625. doi: 10.1007/s00277-022-04854-3.
PMID: 35604472 No abstract available.
4. [Characteristics and clinical outcome of high-risk multiple myeloma patients in Korea \(KMM 1805\).](#)
Kim K, Kim JS, Yoon SS, Yoon DH, Eom HS, Lee JJ, Yim HW, Park M, Lee H, Min CK; Korean Multiple Myeloma Working Party (KMMWP).
Int J Hematol. 2022 Jul;116(1):110-121. doi: 10.1007/s12185-022-03332-w. Epub 2022 May 11.
PMID: 35543899
5. [Outcomes in Refractory Diffuse Large B-Cell Lymphoma: Results from Two Prospective Korean Cohorts.](#)
Yi JH, Jeong SH, Kim SJ, Yoon DH, Kang HJ, Koh Y, Kim JS, Lee WS, Yang DH, Do YR, Kim MK, Yoo KH, Choi YS, Yun WJ, Park Y, Jo JC, Eom HS, Kwak JY, Shin HJ, Park BB, Yi SY, Kwon JH, Oh SY, Kim HJ, Sohn BS, Won JH, Hong DS, Lee HS, Lee GW, Suh C, Kim WS.
Cancer Res Treat. 2022 Apr 22. doi: 10.4143/crt.2022.008. Online ahead of print.
PMID: 35468269
6. [Relapse with plasmacytoma after upfront autologous stem cell transplantation in multiple myeloma.](#)
Chu TH, Jung SH, Kim K, Lee JH, Mun YC, Bang SM, Yoon DH, Lee HS, Min CK, Lee JJ.
Ann Hematol. 2022 Jun;101(6):1217-1226. doi: 10.1007/s00277-022-04776-0. Epub 2022 Apr 21.
PMID: 35445844
7. [Distinct genetic alterations in Burkitt-like lymphoma with 11q aberration and Burkitt lymphoma: a novel case report of composite lymphoma.](#)
Kim M, Hwang HS, Yoon DH, Chun SM, Go H.
Haematologica. 2022 Aug 1;107(8):1999-2003. doi: 10.3324/haematol.2021.280543.
PMID: 35354255 Free PMC article. No abstract available.

8. [Comparison of clinical and laboratory characteristics of nonsecretory multiple myeloma and secretory multiple myeloma in a tertiary care hospital.](#)
Youk HJ, Chu D, Park CJ, Seo EJ, Jang S, Cho YU, Lee JH, Yoon DH, Suh C.
Int J Lab Hematol. 2022 Jun;44(3):582-588. doi: 10.1111/ijlh.13811. Epub 2022 Feb 26.
PMID: 35218612
9. [Pegfilgrastim Prophylaxis is Effective in the Prevention of Febrile Neutropenia and Reduces Mortality in Patients Aged \$\geq 75\$ Years with Diffuse Large B-Cell Lymphoma Treated with R-CHOP: A Prospective Cohort Study.](#)
Jeong SH, Kim SJ, Yoon DH, Park Y, Kang HJ, Koh Y, Lee GW, Lee WS, Yang DH, Do YR, Kim MK, Yoo KH, Choi YS, Yun HJ, Yi JH, Jo JC, Eom HS, Kwak JY, Shin HJ, Park BB, Hyun SY, Yi SY, Kwon JH, Oh SY, Kim HJ, Sohn BS, Won JH, Kim SH, Lee HS, Suh C, Kim WS.
Cancer Res Treat. 2021 Dec 30. doi: 10.4143/crt.2021.1168. Online ahead of print.
PMID: 34990525
10. [Single-Agent Mosunetuzumab Shows Durable Complete Responses in Patients With Relapsed or Refractory B-Cell Lymphomas: Phase I Dose-Escalation Study.](#)
Budde LE, Assouline S, Sehn LH, Schuster SJ, Yoon SS, Yoon DH, Matasar MJ, Bosch F, Kim WS, Nastoupil LJ, Flinn IW, Shadman M, Diefenbach C, O'Hear C, Huang H, Kwan A, Li CC, Piccione EC, Wei MC, Yin S, Bartlett NL.
J Clin Oncol. 2022 Feb 10;40(5):481-491. doi: 10.1200/JCO.21.00931. Epub 2021 Dec 16.
PMID: 34914545 Clinical Trial.
11. [Multicenter retrospective analysis of patients with chronic lymphocytic leukemia in Korea.](#)
Yi JH, Lee GW, Lee JH, Yoo KH, Jung CW, Kim DS, Lee JO, Eom HS, Byun JM, Koh Y, Yoon SS, Kim JS, Kong JH, Yhim HY, Yang DH, Yoon DH, Lim DH, Lee WS, Shin HJ.
Blood Res. 2021 Dec 31;56(4):243-251. doi: 10.5045/br.2021.2021102.
PMID: 34801988 Free PMC article.
12. [BCL2 super-expressor diffuse large B-cell lymphoma: a distinct subgroup associated with poor prognosis.](#)
Roh J, Cho H, Pak HK, Lee YS, Lee SW, Ryu JS, Chae EJ, Kim KW, Huh J, Choi YS, Jeong SH, Suh C, Yoon DH, Park CS.
Mod Pathol. 2022 Apr;35(4):480-488. doi: 10.1038/s41379-021-00962-z. Epub 2021 Nov 11.
PMID: 34764434
13. [Significance of Single-cell Level Dual Expression of BCL2 and MYC Determined With Multiplex Immunohistochemistry in Diffuse Large B-Cell Lymphoma.](#)
Roh J, Yoon DH, Lee YK, Pak HK, Kim SY, Han JH, Park JS, Jeong SH, Choi YS, Cho H, Suh C, Huh J, Lee DH, Park CS.
Am J Surg Pathol. 2022 Mar 1;46(3):289-299. doi: 10.1097/PAS.0000000000001830.
PMID: 34739417
14. [Upward trend in follicular lymphoma among the Korean population: 10-year experience at a large tertiary institution.](#)
Kim M, Hwang HS, Cho H, Yoon DH, Suh C, Park CS, Go H, Huh J.
J Pathol Transl Med. 2021 Sep;55(5):330-337. doi: 10.4132/jptm.2021.07.25. Epub 2021 Sep 2.
PMID: 34465079 Free PMC article.
15. [Multicenter, phase II study of response-adapted lenalidomide-based therapy for transplant-ineligible patients with newly diagnosed multiple myeloma without high-risk features.](#)
Yoo KH, Yoon DH, Kang HJ, Lee WS, Kim K, Kim JS, Kim JA, Kim SH, Kwak JY, Kim YS, Min CK, Lee JJ, Yoon SS, Suh C, Baz R, Lee JH.
Curr Probl Cancer. 2022 Feb;46(1):100788. doi: 10.1016/j.currproblcancer.2021.100788.
Epub 2021 Aug 21.
PMID: 34454742 Clinical Trial.
16. [Comprehensive analysis of peripheral T-cell and natural killer/T-cell lymphoma in Asian patients: A multinational, multicenter, prospective registry study in Asia.](#)
Yoon SE, Song Y, Kim SJ, Yoon DH, Chen TY, Koh Y, Kang KW, Lee HS, Tay KKW, Lim

- ST, Poon M, Irawan C, Zhao W, Do YR, Lee MH, Ng SC, Lee WS, Guo Y, Zhang H, Kang HJ, Yun HJ, Kim HJ, Lung DTC, Kwak JY, Han JJ, Mun YC, Oh SY, Shim H, Kwon JH, Sohn BS, Park SK, Jo JC, Ko YH, Jun Z, Kim WS.
Lancet Reg Health West Pac. 2021 Mar 22;10:100126. doi: 10.1016/j.lanwpc.2021.100126. eCollection 2021 May.
PMID: 34327343 Free PMC article.
17. [Autologous EBV-specific T cell treatment results in sustained responses in patients with advanced extranodal NK/T lymphoma: results of a multicenter study.](#)
Kim WS, Oki Y, Kim SJ, Yoon SE, Ardeshta KM, Lin Y, Ruan J, Porcu P, Brammer JE, Jacobsen ED, Yoon DH, Suh C, Suarez F, Radford J, Budde LE, Kim JS, Bachy E, Lee HJ, Bollard CM, Jaccard A, Kang HJ, Inman S, Murray M, Combs KE, Lee DY, Advani R, Gunter KC, Rooney CM, Heslop HE.
Ann Hematol. 2021 Oct;100(10):2529-2539. doi: 10.1007/s00277-021-04558-0. Epub 2021 Jul 24.
PMID: 34304287 Clinical Trial.
 18. [Cutaneous T-cell lymphoma in Asian patients: a multinational, multicenter, prospective registry study in Asia.](#)
Lee YP, Yoon SE, Song Y, Kim SJ, Yoon DH, Chen TY, Koh YI, Kang KW, Lee HS, Wei KTK, Lim ST, Poon M, Irawan C, Zhao W, Do YR, Lee MH, Ng SC, Lee WS, Guo Y, Zhang H, Kang HJ, Yun HJ, Kim HJ, Lung DTC, Kwak JY, Han JJ, Mun YC, Oh SY, Shim H, Kwon JH, Sohn BS, Park SK, Jo JC, Ko YH, Jun Z, Kim WS.
Int J Hematol. 2021 Sep;114(3):355-362. doi: 10.1007/s12185-021-03179-7. Epub 2021 Jul 24.
PMID: 34302593
 19. [Efficacy and safety of prophylactic high-dose MTX in high-risk DLBCL: a treatment intent-based analysis.](#)
Jeong H, Cho H, Kim H, Chae H, Lee JB, Lee K, Kim S, Lee SW, Ryu JS, Kim KW, Chae EJ, Huh J, Park CS, Yoon DH, Suh C.
Blood Adv. 2021 Apr 27;5(8):2142-2152. doi: 10.1182/bloodadvances.2020003947.
PMID: 33881464 Free PMC article.
 20. [The limited role of comprehensive staging work-up in ocular adnexal extranodal marginal zone lymphoma of mucosa-associated lymphoid tissue type \(MALToma\) with excellent prognosis.](#)
Chae H, Cho H, Sa HS, Kim KW, Chae EJ, Ryu JS, Park CS, Huh J, Jang S, Yoon DH, Suh C.
Br J Haematol. 2021 May;193(4):848-851. doi: 10.1111/bjh.17411. Epub 2021 Mar 29.
PMID: 33779995 No abstract available.
 21. [Real-world outcomes of ibrutinib therapy in Korean patients with relapsed or refractory mantle cell lymphoma: a multicenter, retrospective analysis.](#)
Yi JH, Kim SJ, Yoon DH, Suh C, Chang MH, Yang DH, Jo JC, Hyun SY, Eom HS, Lee JO, Kwon JH, Han SH, Lee SS, Kwak JY, Kim SH, Kim DS, Lee JH, Oh SY, Ryoo HM, Kim HJ, Kim WS.
Cancer Commun (Lond). 2021 Mar;41(3):275-278. doi: 10.1002/cac2.12150. Epub 2021 Feb 24.
PMID: 33626235 Free PMC article. No abstract available.
 22. [ROBUST: A Phase III Study of Lenalidomide Plus R-CHOP Versus Placebo Plus R-CHOP in Previously Untreated Patients With ABC-Type Diffuse Large B-Cell Lymphoma.](#)
Nowakowski GS, Chiappella A, Gascoyne RD, Scott DW, Zhang Q, Jurczak W, Özcan M, Hong X, Zhu J, Jin J, Belada D, Bergua JM, Piazza F, Mócikova H, Molinari AL, Yoon DH, Cavallo F, Tani M, Yamamoto K, Izutsu K, Kato K, Czuczman M, Hersey S, Kilcoyne A, Russo J, Hudak K, Zhang J, Wade S, Witzig TE, Vitolo U.
J Clin Oncol. 2021 Apr 20;39(12):1317-1328. doi: 10.1200/JCO.20.01366. Epub 2021 Feb 23.
PMID: 33621109 Free PMC article. Clinical Trial.
 23. [Daratumumab monotherapy for patients with relapsed or refractory natural killer/T-cell lymphoma, nasal type: an open-label, single-arm, multicenter, phase 2 study.](#)

- Huang H, Zhu J, Yao M, Kim TM, Yoon DH, Cho SG, Eom HS, Lim ST, Yeh SP, Song Y, Kwong YL, Kim JS, Jin J, Shi Y, Kim H, Qing M, Zhou T, Gao G, Dong Z, Qi M, Kim WS. *J Hematol Oncol*. 2021 Feb 15;14(1):25. doi: 10.1186/s13045-020-01020-y. PMID: 33588922 Free PMC article. Clinical Trial.
24. [Reappraisal of the prognostic value of Epstein-Barr virus status in monomorphic post-transplantation lymphoproliferative disorders-diffuse large B-cell lymphoma.](#)
Kim JH, Cho H, Sung H, Jung AR, Lee YS, Lee SW, Ryu JS, Chae EJ, Kim KW, Huh J, Park CS, Yoon DH, Suh C. *Sci Rep*. 2021 Feb 3;11(1):2880. doi: 10.1038/s41598-021-82534-4. PMID: 33536508 Free PMC article.
 25. [Assessment of naive indolent lymphoma using whole-body diffusion-weighted imaging and T2-weighted MRI: results of a prospective study in 30 patients.](#)
Hong GS, Chae EJ, Ryu JS, Chae SY, Lee HS, Yoon DH, Suh C. *Cancer Imaging*. 2021 Jan 7;21(1):5. doi: 10.1186/s40644-020-00371-6. PMID: 33413685 Free PMC article.
 26. [Prognostic Stratification of Patients with Burkitt Lymphoma Using Serum \$\beta\$ 2-microglobulin Levels.](#)
Kim HD, Cho H, Kim S, Lee K, Kang EH, Park JS, Park CS, Huh J, Ryu JS, Lee SW, Yoon DH, Kim SJ, Ko YH, Kim WS, Suh C. *Cancer Res Treat*. 2021 Jul;53(3):847-856. doi: 10.4143/crt.2020.1060. Epub 2020 Dec 17. PMID: 33332932 Free PMC article.
 27. [Superiority of Epstein-Barr Virus DNA in the Plasma Over Whole Blood for Prognostication of Extranodal NK/T Cell Lymphoma.](#)
Ha JY, Cho H, Sung H, Jung AR, Lee YS, Lee SW, Ryu JS, Chae EJ, Kim KW, Huh J, Park CS, Kim DJ, Kim SO, Yoon DH. *Front Oncol*. 2020 Nov 30;10:594692. doi: 10.3389/fonc.2020.594692. eCollection 2020. PMID: 33330083 Free PMC article.
 28. [Immune Checkpoint Programmed Cell Death Protein-1 \(PD-1\) Expression on Bone Marrow T Cell Subsets in Patients With Plasma Cell Myeloma.](#)
Lee MY, Park CJ, Cho YU, You E, Jang S, Seo EJ, Lee JH, Yoon DH, Suh C. *Ann Lab Med*. 2021 May 1;41(3):259-267. doi: 10.3343/alm.2021.41.3.259. PMID: 33303710 Free PMC article.
 29. [Open-label, single arm, multicenter phase II study of VIDL induction chemotherapy followed by upfront autologous stem cell transplantation in patients with advanced stage extranodal NK/T-cell lymphoma.](#)
Song GY, Yoon DH, Suh C, Moon JH, Baek DW, Kim JS, Lee GW, Yi JH, Park Y, Jung KS, Kim SJ, Yang DH, Kim WS. *Bone Marrow Transplant*. 2021 May;56(5):1205-1208. doi: 10.1038/s41409-020-01160-2. Epub 2020 Dec 4. PMID: 33277620 Free PMC article. Clinical Trial.
 30. [A prognostic index for extranodal marginal-zone lymphoma based on the mucosa-associated lymphoid tissue International Prognostic Index and serum \$\beta\$ 2-microglobulin levels.](#)
Kim HD, Cho H, Jeong H, Bang K, Kim S, Lee K, Kang EH, Park JS, Park CS, Huh J, Ryu JS, Lee SW, Yoon DH, Oh SY, Suh C. *Br J Haematol*. 2021 Apr;193(2):307-315. doi: 10.1111/bjh.17222. Epub 2020 Nov 20. PMID: 33216979 Clinical Trial.
 31. [Assessment of NK Cell Activity Based on NK Cell-Specific Receptor Synergy in Peripheral Blood Mononuclear Cells and Whole Blood.](#)
Kim JM, Yi E, Cho H, Choi WS, Ko DH, Yoon DH, Hwang SH, Kim HS. *Int J Mol Sci*. 2020 Oct 30;21(21):8112. doi: 10.3390/ijms21218112. PMID: 33143099 Free PMC article.
 32. [Long-term follow-up of abbreviated R-CHOP chemoimmunotherapy for completely resected limited-stage diffuse large B cell lymphoma \(CISL 12-09\).](#)

- Kang S, Cho H, Sohn BS, Oh SY, Lee WS, Lee SM, Yang DH, Huh J, Yoon DH, Suh C. *Ann Hematol*. 2020 Dec;99(12):2831-2836. doi: 10.1007/s00277-020-04284-z. Epub 2020 Sep 28.
PMID: 32989495
33. [Prognostic Impact of Age at the Time of Diagnosis in Korean Patients with Diffuse Large B-cell Lymphoma in the Rituximab Era: A Single Institution Study.](#)
Hwang HS, Kim M, Park CS, Yoon DH, Suh C, Huh J, Go H. *Cancer Res Treat*. 2021 Jan;53(1):270-278. doi: 10.4143/crt.2020.626. Epub 2020 Sep 15.
PMID: 32972046 Free PMC article.
34. [Clinicopathological and prognostic significance of BCL2, BCL6, MYC, and IRF4 copy number gains and translocations in follicular lymphoma: a study by FISH analysis.](#)
Kim M, Hwang HS, Son EM, Cho H, Yoon DH, Suh C, Park CS, Go H, Huh J. *Leuk Lymphoma*. 2020 Dec;61(14):3342-3350. doi: 10.1080/10428194.2020.1815017. Epub 2020 Sep 13.
PMID: 32921221
35. [Clinical impact of frailty on treatment outcomes of elderly patients with relapsed and/or refractory multiple myeloma treated with lenalidomide plus dexamethasone.](#)
Lee HS, Kim K, Lee JJ, Yoon SS, Bang SM, Kim JS, Eom HS, Yoon DH, Lee Y, Shin HJ, Park Y, Jo JC, Lee WS, Do YR, Mun YC, Lee MH, Kim HJ, Kim SH, Kim MK, Lim SN, Park SK, Yi JH, Lee JH, Min CK; Korean Multiple Myeloma Working Party (KMMWP). *Int J Hematol*. 2021 Jan;113(1):81-91. doi: 10.1007/s12185-020-02988-6. Epub 2020 Sep 5.
PMID: 32889695
36. [Prognostic value of ¹⁸F-fluorodeoxyglucose positron emission tomography/computed tomography in newly diagnosed multiple myeloma: a systematic review and meta-analysis.](#)
Han S, Woo S, Kim YI, Yoon DH, Ryu JS. *Eur Radiol*. 2021 Jan;31(1):152-162. doi: 10.1007/s00330-020-07177-x. Epub 2020 Aug 18.
PMID: 32809165
37. [Breast implant-associated anaplastic large cell lymphoma: the first South Korean case.](#)
Lee J, Cho H, Yoon DH, Kim EK, Gong G, Suh C, Huh JR. *J Pathol Transl Med*. 2020 Sep;54(5):432-434. doi: 10.4132/jptm.2020.07.01. Epub 2020 Aug 18.
PMID: 32806883 Free PMC article. No abstract available.
38. [First-Line Treatment for Primary Breast Diffuse Large B-Cell Lymphoma Using Immunochemotherapy and Central Nervous System Prophylaxis: A Multicenter Phase 2 Trial.](#)
Yhim HY, Yoon DH, Kim SJ, Yang DH, Eom HS, Kim KH, Park Y, Kim JS, Kim HJ, Suh C, Kim WS, Kwak JY. *Cancers (Basel)*. 2020 Aug 6;12(8):2192. doi: 10.3390/cancers12082192.
PMID: 32781541 Free PMC article.
39. [Quantitative analysis of tumor-specific BCL2 expression in DLBCL: refinement of prognostic relevance of BCL2.](#)
Roh J, Cho H, Yoon DH, Hong JY, Lee AN, Eom HS, Lee H, Park WS, Han JH, Jeong SH, Park JS, Pak HK, Kim SW, Kim SY, Suh C, Huh J, Park CS. *Sci Rep*. 2020 Jun 30;10(1):10680. doi: 10.1038/s41598-020-67738-4.
PMID: 32606309 Free PMC article.
40. [Prediction and prevention of central nervous system relapse in patients with extranodal natural killer/T-cell lymphoma.](#)
Kim H, Jeong H, Yamaguchi M, Sohn I, Yoon SE, Byeon S, Hur JY, Koh Y, Yoon SS, Kim EJ, Oguchi M, Miyazaki K, Taguchi S, Yoon DH, Cho J, Ko YH, Kim SJ, Suzuki R, Kim WS. *Blood*. 2020 Nov 26;136(22):2548-2556. doi: 10.1182/blood.2020005026.
PMID: 32584959

41. [Treatment with intravenous busulfan, melphalan, and etoposide followed by autologous stem cell transplantation in patients with non-Hodgkin's lymphoma: a multicenter study from the consortium for improving survival of lymphoma.](#)
Kim KH, Kim WS, Kim SJ, Yoon DH, Suh C, Kang HJ, Choi CW, Lee HS, Bae SH, Park J, Park EK, Kwak JY, Lee MH, Kang BW, Park SK, Won JH.
Transpl Int. 2020 Oct;33(10):1211-1219. doi: 10.1111/tri.13664. Epub 2020 Jul 23.
PMID: 32479690 Clinical Trial.
42. [A phase II study of ibrutinib in combination with rituximab-cyclophosphamide-doxorubicin hydrochloride-vincristine sulfate-prednisone therapy in Epstein-Barr virus-positive, diffuse large B cell lymphoma \(54179060LYM2003: IVORY study\): results of the final analysis.](#)
Yoon SE, Kim SJ, Yoon DH, Koh Y, Mun YC, Do YR, Choi YS, Yang DH, Kim MK, Lee GW, Suh C, Ko YH, Kim WS.
Ann Hematol. 2020 Jun;99(6):1283-1291. doi: 10.1007/s00277-020-04005-6. Epub 2020 Apr 24.
PMID: 32333154 Free PMC article. Clinical Trial.
43. [Prognostic factors for relapse and survival among patients with ocular adnexal lymphoma: validation of the eighth edition of the American Joint Committee on Cancer \(AJCC\) TNM classification.](#)
Kwon M, Lee JS, Lee C, Yoon DH, Sa HS.
Br J Ophthalmol. 2021 Feb;105(2):279-284. doi: 10.1136/bjophthalmol-2020-315875. Epub 2020 Apr 23.
PMID: 32327417
44. [The clinical outcomes of rituximab biosimilar CT-P10 \(Truxima®\) with CHOP as first-line treatment for patients with diffuse large B-cell lymphoma: real-world experience.](#)
Lee K, Ha JY, Jung AR, Lee YS, Lee SW, Ryu JS, Chae EJ, Kim KW, Huh J, Park CS, Yoon DH, Suh C.
Leuk Lymphoma. 2020 Jul;61(7):1575-1583. doi: 10.1080/10428194.2020.1742906. Epub 2020 Apr 15.
PMID: 32290739
45. [Risk Stratification Using Multivariable Fractional Polynomials in Diffuse Large B-Cell Lymphoma.](#)
Roh J, Jung J, Lee Y, Kim SW, Pak HK, Lee AN, Lee J, Cho J, Cho H, Yoon DH, Park RW, Huh J, Oh HB, Park CS.
Front Oncol. 2020 Mar 11;10:329. doi: 10.3389/fonc.2020.00329. eCollection 2020.
PMID: 32219067 Free PMC article.
46. [Treatment of mantle cell lymphoma in Asia: a consensus paper from the Asian Lymphoma Study Group.](#)
Yoon DH, Cao J, Chen TY, Izutsu K, Kim SJ, Kwong YL, Lin TY, Thye LS, Xu B, Yang DH, Kim WS.
J Hematol Oncol. 2020 Mar 17;13(1):21. doi: 10.1186/s13045-020-00855-9.
PMID: 32183871 Free PMC article. Review.
47. [Role of whole-body MRI for treatment response assessment in multiple myeloma: comparison between clinical response and imaging response.](#)
Park HY, Kim KW, Yoon MA, Lee MH, Chae EJ, Lee JH, Chung HW, Yoon DH.
Cancer Imaging. 2020 Jan 30;20(1):14. doi: 10.1186/s40644-020-0293-6.
PMID: 32000858 Free PMC article.
48. [Pomalidomide, cyclophosphamide, and dexamethasone for elderly patients with relapsed and refractory multiple myeloma: A study of the Korean Multiple Myeloma Working Party \(KMMWP-164 study\).](#)
Lee HS, Kim K, Kim SJ, Lee JJ, Kim I, Kim JS, Eom HS, Yoon DH, Suh C, Shin HJ, Mun YC, Kim MK, Lim SN, Choi CW, Kang HJ, Yoon SS, Min CK; Korean Multiple Myeloma Working Party (KMMWP).
Am J Hematol. 2020 Apr;95(4):413-421. doi: 10.1002/ajh.25726. Epub 2020 Jan 24.
PMID: 31919872 Free PMC article. Clinical Trial.
49. [Distinct clinical characteristics at diagnosis in patients with late relapses compared with early relapses of diffuse large B-cell lymphoma treated with R-CHOP.](#)

- Kang J, Chae H, Hong JY, Yoon DH, Kim S, Park JS, Lee SW, Park CS, Ryu JS, Huh J, Suh C.
Leuk Lymphoma. 2020 May;61(5):1119-1125. doi: 10.1080/10428194.2019.1709831.
Epub 2020 Jan 6.
PMID: 31905296
50. [A phase II study of etoposide, methylprednisolone, high-dose cytarabine, and oxaliplatin \(ESHAOx\) for patients with refractory or relapsed Hodgkin's lymphoma.](#)
Won YW, Lee H, Eom HS, Kim JS, Suh C, Yoon DH, Hong JY, Kang HJ, Lee JH, Kim WS, Kim SJ, Lee WS, Chang MH, Do YR, Yi JH, Kim I, Won JH, Kim K, Oh SY, Jo JC.
Ann Hematol. 2020 Feb;99(2):255-264. doi: 10.1007/s00277-019-03891-9. Epub 2020 Jan 2.
PMID: 31897676 Clinical Trial.
 51. [Pralatrexate in patients with recurrent or refractory peripheral T-cell lymphomas: a multicenter retrospective analysis.](#)
Hong JY, Yoon DH, Yoon SE, Kim SJ, Lee HS, Eom HS, Lee HW, Shin DY, Koh Y, Yoon SS, Jo JC, Kim JS, Kim SJ, Cho SH, Lee WS, Won JH, Kim WS, Suh C.
Sci Rep. 2019 Dec 30;9(1):20302. doi: 10.1038/s41598-019-56891-0.
PMID: 31889144 Free PMC article.
 52. [The effectiveness and safety of lenalidomide and dexamethasone in patients with relapsed/refractory multiple myeloma in real-world clinical practice: a study of the Korean Multiple Myeloma Working Party \(KMMWP-151 study\).](#)
Jo JC, Lee HS, Kim K, Lee JJ, Yoon SS, Bang SM, Kim JS, Eom HS, Yoon DH, Lee Y, Shin HJ, Park Y, Lee WS, Do YR, Mun YC, Lee MH, Kim HJ, Kim SH, Kim MK, Lim SN, Cho SH, Park SK, Yi JH, Lee JH, Kim J, Min CK; Korean Multiple Myeloma Working Party (KMMWP).
Ann Hematol. 2020 Feb;99(2):309-319. doi: 10.1007/s00277-019-03904-7. Epub 2019 Dec 23.
PMID: 31872360 Clinical Trial.
 53. [Clinical, Laboratory, and Bone Marrow Findings of 31 Patients With Waldenström Macroglobulinemia.](#)
Ahn A, Park CJ, Cho YU, Jang S, Seo EJ, Lee JH, Yoon DH, Suh C.
Ann Lab Med. 2020 May;40(3):193-200. doi: 10.3343/alm.2020.40.3.193.
PMID: 31858758 Free PMC article.
 54. [Ruxolitinib shows activity against Hodgkin lymphoma but not primary mediastinal large B-cell lymphoma.](#)
Kim SJ, Yoon DH, Kang HJ, Hong JY, Lee HS, Oh SY, Shin HJ, Kong JH, Yi JH, Sakamoto K, Ko YH, Huh J, Lee SS, Takeuchi K, Shin DY, Suh C, Kim WS.
BMC Cancer. 2019 Nov 10;19(1):1080. doi: 10.1186/s12885-019-6303-z.
PMID: 31707975 Free PMC article. Clinical Trial.
 55. [Phase II study of R-CVP followed by rituximab maintenance therapy for patients with advanced marginal zone lymphoma: consortium for improving survival of lymphoma \(CISL\) study.](#)
Oh SY, Kim WS, Kim JS, Kim SJ, Yoon DH, Yang DH, Lee WS, Kim HJ, Yhim HY, Jeong SH, Won JH, Lee S, Kong JH, Lim SN, Ji JH, Kwon KA, Lee GW, Lee JH, Lee HS, Shin HJ, Suh C.
Cancer Commun (Lond). 2019 Oct 16;39(1):58. doi: 10.1186/s40880-019-0403-7.
PMID: 31619290 Free PMC article. Clinical Trial.
 56. [A Randomized Phase III Trial on the Role of Esophagectomy in Complete Responders to Preoperative Chemoradiotherapy for Esophageal Squamous Cell Carcinoma \(ESOPRESSO\).](#)
Park SR, Yoon DH, Kim JH, Kim YH, Kim HR, Lee HJ, Jung HY, Lee GH, Song HJ, Kim DH, Choi KD, Lee JH, Ahn JY, Ryu JS, Cho KJ, Kim SB.
Anticancer Res. 2019 Sep;39(9):5123-5133. doi: 10.21873/anticancerres.13707.
PMID: 31519624 Clinical Trial.
 57. [Multicenter retrospective analysis of the clinicopathologic features of monomorphic epitheliotropic intestinal T-cell lymphoma.](#)

- Yi JH, Lee GW, Do YR, Jung HR, Hong JY, Yoon DH, Suh C, Choi YS, Yi SY, Sohn BS, Kim BS, Oh SY, Park J, Jo JC, Lee SS, Oh YH, Kim SJ, Kim WS.
Ann Hematol. 2019 Nov;98(11):2541-2550. doi: 10.1007/s00277-019-03791-y. Epub 2019 Sep 6.
PMID: 31493002 Clinical Trial.
58. [Efficacy of Brentuximab Vedotin in Relapsed or Refractory High-CD30-Expressing Non-Hodgkin Lymphomas: Results of a Multicenter, Open-Labeled Phase II Trial.](#)
Kim SJ, Yoon DH, Kim JS, Kang HJ, Lee HW, Eom HS, Hong JY, Cho J, Ko YH, Huh J, Yang WI, Park WS, Lee SS, Suh C, Kim WS.
Cancer Res Treat. 2020 Apr;52(2):374-387. doi: 10.4143/crt.2019.198. Epub 2019 Aug 13.
PMID: 31476851 Free PMC article. Clinical Trial.
59. [JL1 Antigen Expression on Bone Marrow Lymphoma Cells from Patients With Non-Hodgkin Lymphoma.](#)
Kim MS, Park CJ, Cho YU, Jang S, Seo EJ, Park CS, Huh J, Im HJ, Seo JJ, Yoon DH, Suh C.
Ann Lab Med. 2020 Jan;40(1):1-6. doi: 10.3343/alm.2020.40.1.1.
PMID: 31432632 Free PMC article.
60. [Systemic HD-MTX for CNS prophylaxis in high-risk DLBCL patients: a prospectively collected, single-center cohort analysis.](#)
Lee K, Yoon DH, Hong JY, Kim S, Lee K, Kang EH, Huh J, Park CS, Lee SW, Suh C.
Int J Hematol. 2019 Jul;110(1):86-94. doi: 10.1007/s12185-019-02653-7. Epub 2019 May 21.
PMID: 31115880
61. [Efficacy of the novel CDK7 inhibitor QS1189 in mantle cell lymphoma.](#)
Choi YJ, Kim DH, Yoon DH, Suh C, Choi CM, Lee JC, Hong JY, Rho JK.
Sci Rep. 2019 May 10;9(1):7193. doi: 10.1038/s41598-019-43760-z.
PMID: 31076643 Free PMC article.
62. [Thiotepa, busulfan, and cyclophosphamide or busulfan, cyclophosphamide, and etoposide high-dose chemotherapy followed by autologous stem cell transplantation for consolidation of primary central nervous system lymphoma.](#)
Hyung J, Hong JY, Yoon DH, Kim S, Park JS, Park CS, Lee SW, Kim JH, Ryu JS, Huh J, Suh C.
Ann Hematol. 2019 Jul;98(7):1657-1664. doi: 10.1007/s00277-019-03667-1. Epub 2019 Apr 15.
PMID: 30989325
63. [Pharmacokinetic and pharmacodynamic study of lenograstim for hematopoietic stem cell mobilization: a prospective randomized study for optimal apheresis.](#)
Kang J, Hong JY, Yoon DH, Kim JE, Kim KP, Kim S, Lee KM, Park JS, Lee JS, Suh C.
Transfusion. 2019 May;59(5):1781-1788. doi: 10.1111/trf.15265. Epub 2019 Mar 29.
PMID: 30924165 Clinical Trial.
64. [Feasibility of reduced-dose CT of the head and neck with iterative reconstruction: a phantom and prospective clinical study.](#)
Chung MS, Choi YJ, Hwang JY, Yoon DH, Seo KJ, Lee JH, Baek JH.
Acta Radiol. 2019 Nov;60(11):1457-1464. doi: 10.1177/0284185119830276. Epub 2019 Feb 18.
PMID: 30776905 No abstract available.
65. [Cluster Containing More Than 20 CD3-Positive Cells in Bone Marrow Biopsy Is a Candidate Prognostic Indicator in Peripheral T-Cell Lymphoma, Not Otherwise Specified.](#)
Shim H, Jang S, Huh J, Yoon DH, Suh C, Park CJ.
Ann Lab Med. 2019 Mar;39(2):200-204. doi: 10.3343/alm.2019.39.2.200.
PMID: 30430783 Free PMC article.
66. [Venous thromboembolism in relapsed or refractory multiple myeloma patients treated with lenalidomide plus dexamethasone.](#)
Shin J, Lee JJ, Kim K, Min CK, Lee JO, Suh C, Kim JS, Lee YJ, Yoon SS, Jo JC, Lee HS, Bang SM; Korean Multiple Myeloma 151 Investigators.

- Int J Hematol. 2019 Jan;109(1):79-90. doi: 10.1007/s12185-018-2540-1. Epub 2018 Oct 5. PMID: 30291558
67. [The cell-of-origin classification of diffuse large B cell lymphoma in a Korean population by the Lymph2Cx assay and its correlation with immunohistochemical algorithms.](#)
Hwang HS, Yoon DH, Hong JY, Park CS, Lee YS, Ko YH, Kim SJ, Kim WS, Suh C, Huh J. Ann Hematol. 2018 Dec;97(12):2363-2372. doi: 10.1007/s00277-018-3442-2. Epub 2018 Aug 1. PMID: 30069703 Clinical Trial.
68. [Treating synchronous bilateral ocular adnexal marginal zone lymphoma: the consortium for improving survival of lymphoma study.](#)
Oh SY, Kim WS, Kang HJ, Lee JH, Huh SJ, Kim SJ, Yoon DH, Hong JY, Lee WS, Kim HJ, Won JH, Park BB, Lee SI, Suh C. Ann Hematol. 2018 Oct;97(10):1851-1857. doi: 10.1007/s00277-018-3387-5. Epub 2018 Jun 11. PMID: 29947974
69. [Efficacy and Survival Outcome Associated with the Use of Novel Agents and Autologous Stem Cell Transplantation in Cases of Immunoglobulin D Multiple Myeloma in Korea.](#)
Kang J, Hong JY, Yoon DH, Kim S, Lee KM, Park JS, Park CJ, Min WK, Seo EJ, Jang S, Suh C. Acta Haematol. 2018;139(3):185-192. doi: 10.1159/000486664. Epub 2018 Apr 10. PMID: 29635247
70. [Bendamustine plus rituximab for relapsed or refractory diffuse large B cell lymphoma: a multicenter retrospective analysis.](#)
Hong JY, Yoon DH, Suh C, Kim WS, Kim SJ, Jo JC, Kim JS, Lee WS, Oh SY, Park Y, Kim SY, Lee MH, Lee HS, Do YR. Ann Hematol. 2018 Aug;97(8):1437-1443. doi: 10.1007/s00277-018-3317-6. Epub 2018 Apr 4. PMID: 29619501
71. [Phase I study of CKD-581, a pan-histone deacetylase inhibitor, in patients with lymphoma or multiple myeloma refractory to standard therapy.](#)
Cho H, Yoon DH, Kim KP, Bae KS, Kim WS, Eom HS, Kim JS, Hong JY, Kim SJ, Lee H, Kim SJ, Suh C. Invest New Drugs. 2018 Oct;36(5):877-885. doi: 10.1007/s10637-018-0582-0. Epub 2018 Mar 9. PMID: 29520651 Clinical Trial.
72. [Incorporation of Immune Checkpoint Blockade into Chimeric Antigen Receptor T Cells \(CAR-Ts\): Combination or Built-In CAR-T.](#)
Yoon DH, Osborn MJ, Tolar J, Kim CJ. Int J Mol Sci. 2018 Jan 24;19(2):340. doi: 10.3390/ijms19020340. PMID: 29364163 Free PMC article. Review.
73. [Primary central nervous system lymphoma: a new prognostic model for patients with diffuse large B-cell histology.](#)
Ahn Y, Ahn HJ, Yoon DH, Hong JY, Yoo C, Kim S, Huh J, Suh C. Blood Res. 2017 Dec;52(4):285-292. doi: 10.5045/br.2017.52.4.285. Epub 2017 Dec 26. PMID: 29333405 Free PMC article.
74. [Treatment outcomes of dose-attenuated CHOP chemotherapy in elderly patients with peripheral T cell lymphoma.](#)
Choi EJ, Hong JY, Yoon DH, Kang J, Park CS, Huh J, Chae EJ, Lee Y, Ryu JS, Suh C. Blood Res. 2017 Dec;52(4):270-275. doi: 10.5045/br.2017.52.4.270. Epub 2017 Dec 26. PMID: 29333403 Free PMC article.
75. [Clinical characteristics and outcomes of patients with chronic disseminated candidiasis who need adjuvant corticosteroid therapy.](#)
Jang YR, Kim MC, Kim T, Chong YP, Lee SO, Choi SH, Kim YS, Woo JH, Hong JY, Yoon DH, Suh C, Lee JH, Lee JH, Lee KH, Kim SH. Med Mycol. 2018 Aug 1;56(6):782-786. doi: 10.1093/mmy/myx110.

- PMID: 29228331
76. [Increased circulating plasma cells detected by flow cytometry predicts poor prognosis in patients with plasma cell myeloma.](#)
Bae MH, Park CJ, Kim BH, Cho YU, Jang S, Lee DH, Seo EJ, Yoon DH, Lee JH, Suh C. Cytometry B Clin Cytom. 2018 May;94(3):493-499. doi: 10.1002/cyto.b.21606. Epub 2017 Dec 29.
PMID: 29220877
77. [Improved prognostic stratification using NCCN- and GELTAMO-international prognostic index in patients with diffuse large B-cell lymphoma.](#)
Hong J, Kim SJ, Chang MH, Kim JA, Kwak JY, Kim JS, Yoon DH, Lee WS, Do YR, Kang HJ, Eom HS, Park Y, Won JH, Mun YC, Kim HJ, Kwon JH, Kong JH, Oh SY, Lee S, Bae SH, Yang DH, Jun HJ, Lee HS, Yun HJ, Lee SI, Kim MK, Yi JH, Lee JH, Kim WS, Suh C. Oncotarget. 2017 Sep 18;8(54):92171-92182. doi: 10.18632/oncotarget.20988. eCollection 2017 Nov 3.
PMID: 29190906 Free PMC article.
78. [Effect of an Arm Traction Device on Image Quality and Radiation Exposure during Neck CT: A Prospective Study.](#)
Choi YJ, Lee JH, Yoon DH, Kim HJ, Seo KJ, Do KH, Baek JH. AJNR Am J Neuroradiol. 2018 Jan;39(1):151-155. doi: 10.3174/ajnr.A5418. Epub 2017 Nov 9.
PMID: 29122761 Free PMC article. Clinical Trial.
79. [Sequential heart and autologous stem cell transplantation for light-chain cardiac amyloidosis.](#)
Huh JY, Seo S, Suh C, Huh J, Yoon DH, Kim JJ. Blood Res. 2017 Sep;52(3):221-224. doi: 10.5045/br.2017.52.3.221. Epub 2017 Sep 25.
PMID: 29043240 Free PMC article. No abstract available.
80. [Platelet to lymphocyte ratio \(PLR\) retains independent prognostic significance in advanced stage marginal zone lymphoma patients treated with rituximab, cyclophosphamide, vincristine, and prednisone combination chemotherapy \(R-CVP\): Consortium for Improving Survival of Lymphoma trial.](#)
Seo J, Kim WS, Kim JS, Kim SJ, Lee JH, Hong JS, Lee GW, Oh SY, Lee JH, Yoon DH, Lee WS, Kim HJ, Kwak JY, Kang HJ, Jo JC, Park Y, Lee HS, Kim HJ, Suh C. Blood Res. 2017 Sep;52(3):200-206. doi: 10.5045/br.2017.52.3.200. Epub 2017 Sep 25.
PMID: 29043235 Free PMC article.
81. [The immune checkpoint molecule V-set Ig domain-containing 4 is an independent prognostic factor for multiple myeloma.](#)
Roh J, Jeon Y, Lee AN, Lee SM, Kim Y, Sung CO, Park CJ, Hong JY, Yoon DH, Suh C, Huh J, Choi I, Park CS. Oncotarget. 2017 Jul 22;8(35):58122-58132. doi: 10.18632/oncotarget.19468. eCollection 2017 Aug 29.
PMID: 28938542 Free PMC article.
82. [Beyond first-line non-anthracycline-based chemotherapy for extranodal NK/T-cell lymphoma: clinical outcome and current perspectives on salvage therapy for patients after first relapse and progression of disease.](#)
Lim SH, Hong JY, Lim ST, Hong H, Arnoud J, Zhao W, Yoon DH, Tang T, Cho J, Park S, Ko YH, Kim SJ, Suh C, Lin T, Kim WS. Ann Oncol. 2017 Sep 1;28(9):2199-2205. doi: 10.1093/annonc/mdx316.
PMID: 28911074
83. [PD-L1 expression correlates with VEGF and microvessel density in patients with uniformly treated classical Hodgkin lymphoma.](#)
Koh YW, Han JH, Yoon DH, Suh C, Huh J. Ann Hematol. 2017 Nov;96(11):1883-1890. doi: 10.1007/s00277-017-3115-6. Epub 2017 Aug 25.
PMID: 28842748
84. [Comprehensive evaluation of the revised international staging system in multiple myeloma](#)

- [patients treated with novel agents as a primary therapy.](#)
Cho H, Yoon DH, Lee JB, Kim SY, Moon JH, Do YR, Lee JH, Park Y, Lee HS, Eom HS, Shin HJ, Min CK, Kim JS, Jo JC, Kang HJ, Mun YC, Lee WS, Lee JJ, Suh C, Kim K; and the Korean Multiple Myeloma Working Party.
Am J Hematol. 2017 Dec;92(12):1280-1286. doi: 10.1002/ajh.24891. Epub 2017 Sep 8.
PMID: 28833417
85. [Epstein-Barr virus positivity is associated with angiogenesis in, and poorer survival of, patients receiving standard treatment for classical Hodgkin's lymphoma.](#)
Koh YW, Han JH, Yoon DH, Suh C, Huh J.
Hematol Oncol. 2018 Feb;36(1):182-188. doi: 10.1002/hon.2468. Epub 2017 Jul 26.
PMID: 28744882
86. [Interim ¹⁸F-FDG PET/CT may not predict the outcome in primary central nervous system lymphoma patients treated with sequential treatment with methotrexate and cytarabine.](#)
Jo JC, Yoon DH, Kim S, Lee K, Kang EH, Park JS, Ryu JS, Huh J, Park CS, Kim JH, Lee SW, Suh C.
Ann Hematol. 2017 Sep;96(9):1509-1515. doi: 10.1007/s00277-017-3068-9. Epub 2017 Jul 19.
PMID: 28725988
87. [Clinical characteristics, treatment, and outcome of primary rectal lymphoma: a single center experience of 16 patients.](#)
Jeong JH, Kim S, Kim JE, Yoon DH, Lee SW, Huh J, Suh C.
Blood Res. 2017 Jun;52(2):125-129. doi: 10.5045/br.2017.52.2.125. Epub 2017 Jun 22.
PMID: 28698849 Free PMC article.
88. [Electrophysiologic features of POEMS syndrome compared with MGUS-related neuropathy.](#)
Kim H, Lim YM, Jin JY, Yoon DH, Suh C, Kim SY, Jo JC, Kim KK.
Muscle Nerve. 2017 Dec;56(6):E73-E77. doi: 10.1002/mus.25684. Epub 2017 May 30.
PMID: 28472865
89. [GLUT1 as a Prognostic Factor for Classical Hodgkin's Lymphoma: Correlation with PD-L1 and PD-L2 Expression.](#)
Koh YW, Han JH, Park SY, Yoon DH, Suh C, Huh J.
J Pathol Transl Med. 2017 Mar;51(2):152-158. doi: 10.4132/jptm.2016.11.03. Epub 2017 Feb 21.
PMID: 28219001 Free PMC article.
90. [Sexual problems in male vs. female non-Hodgkin lymphoma survivors: prevalence, correlates, and associations with health-related quality of life.](#)
Kim IR, Kim SH, Ok ON, Kim SH, Lee S, Choi E, Kim SJ, Yoon DH, Lee MH.
Ann Hematol. 2017 May;96(5):739-747. doi: 10.1007/s00277-017-2940-y. Epub 2017 Feb 9.
PMID: 28184983
91. [Feasibility of abbreviated cycles of immunochemotherapy for completely resected limited-stage CD20+ diffuse large B-cell lymphoma \(CISL 12-09\).](#)
Yoon DH, Sohn BS, Oh SY, Lee WS, Lee SM, Yang DH, Huh J, Suh C.
Oncotarget. 2017 Feb 21;8(8):13367-13374. doi: 10.18632/oncotarget.14531.
PMID: 28076329 Free PMC article. Clinical Trial.
92. [Efficacy and toxicity of the combination chemotherapy of thalidomide, alkylating agent, and steroid for relapsed/refractory myeloma patients: a report from the Korean Multiple Myeloma Working Party \(KMMWP\) retrospective study.](#)
Kwon J, Min CK, Kim K, Han JJ, Moon JH, Kang HJ, Eom HS, Kim MK, Kim HJ, Yoon DH, Lee JO, Lee WS, Lee JH, Lee JJ, Choi YS, Kim SH, Yoon SS.
Cancer Med. 2017 Jan;6(1):100-108. doi: 10.1002/cam4.970. Epub 2016 Dec 1.
PMID: 27905203 Free PMC article.
93. [Methotrexate elimination and toxicity: MTHFR 677C>T polymorphism in patients with primary CNS lymphoma treated with high-dose methotrexate.](#)
Choi YJ, Park H, Lee JS, Lee JY, Kim S, Kim TW, Park JS, Kim JE, Yoon DH, Suh C.

- Hematol Oncol. 2017 Dec;35(4):504-509. doi: 10.1002/hon.2363. Epub 2016 Oct 25.
PMID: 27781293
94. [Prognostic significance of serum beta-2 microglobulin in patients with diffuse large B-cell lymphoma in the rituximab era.](#)
Seo S, Hong JY, Yoon S, Yoo C, Park JH, Lee JB, Park CS, Huh J, Lee Y, Kim KW, Ryu JS, Kim SJ, Kim WS, Yoon DH, Suh C.
Oncotarget. 2016 Nov 22;7(47):76934-76943. doi: 10.18632/oncotarget.12734.
PMID: 27764777 Free PMC article.
95. [Bendamustine in heavily pre-treated multiple myeloma patients: Results of a retrospective analysis from the Korean Multiple Myeloma Working Party.](#)
Kim SJ, Bang SM, Choi YS, Jo DY, Kim JS, Lee H, Eom HS, Yoon DH, Suh C, Lee JJ, Hong J, Lee JH, Koh Y, Kim K, Yoon SS, Min CK; Korean Multiple Myeloma Working Party.
Blood Res. 2016 Sep;51(3):193-199. doi: 10.5045/br.2016.51.3.193. Epub 2016 Sep 23.
PMID: 27722131 Free PMC article.
96. [Highly elevated serum lactate dehydrogenase is associated with central nervous system relapse in patients with diffuse large B-cell lymphoma: Results of a multicenter prospective cohort study.](#)
Kim SJ, Hong JS, Chang MH, Kim JA, Kwak JY, Kim JS, Yoon DH, Lee WS, Do YR, Kang HJ, Eom HS, Park Y, Won JH, Mun YC, Kim HJ, Kwon JH, Kong JH, Oh SY, Lee S, Bae SH, Yang DH, Jun HJ, Kim YS, Yun HJ, Lee SI, Kim MK, Park EK, Kim WS, Suh C.
Oncotarget. 2016 Nov 1;7(44):72033-72043. doi: 10.18632/oncotarget.12459.
PMID: 27713132 Free PMC article.
97. [A Randomized Feasibility Study of ¹⁸F-Fluoroestradiol PET to Predict Pathologic Response to Neoadjuvant Therapy in Estrogen Receptor-Rich Postmenopausal Breast Cancer.](#)
Chae SY, Kim SB, Ahn SH, Kim HO, Yoon DH, Ahn JH, Jung KH, Han S, Oh SJ, Lee SJ, Kim HJ, Son BH, Gong G, Lee HS, Moon DH.
J Nucl Med. 2017 Apr;58(4):563-568. doi: 10.2967/jnumed.116.178368. Epub 2016 Sep 29.
PMID: 27688475 Clinical Trial.
98. [Phase II trial of concurrent chemoradiotherapy with L-asparaginase and MIDDLE chemotherapy for newly diagnosed stage I/II extranodal NK/T-cell lymphoma, nasal type \(CISL-1008\).](#)
Yoon DH, Kim SJ, Jeong SH, Shin DY, Bae SH, Hong J, Park SK, Yhim HY, Yang DH, Lee H, Kang HJ, Lee MH, Eom HS, Kwak JY, Lee JH, Suh C, Kim WS.
Oncotarget. 2016 Dec 20;7(51):85584-85591. doi: 10.18632/oncotarget.11319.
PMID: 27542213 Free PMC article. Clinical Trial.
99. [RGS1 expression is associated with poor prognosis in multiple myeloma.](#)
Roh J, Shin SJ, Lee AN, Yoon DH, Suh C, Park CJ, Huh J, Park CS.
J Clin Pathol. 2017 Mar;70(3):202-207. doi: 10.1136/jclinpath-2016-203713. Epub 2016 Jul 21.
PMID: 27445341
100. [Recurrence patterns of mucosa-associated lymphoid tissue lymphoma after definitive radiation treatment: A single center experience.](#)
Joo JH, Lee SW, Huh J, Suh C, Yoon DH, Ahn SD, Choi EK, Kim JH.
Hematology. 2016 Oct;21(9):542-8. doi: 10.1080/10245332.2016.1164933. Epub 2016 May 10.
PMID: 27168138
101. [A new extranodal scoring system based on the prognostically relevant extranodal sites in diffuse large B-cell lymphoma, not otherwise specified treated with chemoimmunotherapy.](#)
Hwang HS, Yoon DH, Suh C, Huh J.
Ann Hematol. 2016 Aug;95(8):1249-58. doi: 10.1007/s00277-016-2689-8. Epub 2016 May 11.
PMID: 27167532

102. [Bone marrow involvement is not associated with the clinical outcomes of gastric mucosa-associated lymphoid tissue lymphoma.](#)
Gong EJ, Ahn JY, Jung HY, Jung K, Cho CJ, Na HK, Jung KW, Kim do H, Lee JH, Choi KD, Song HJ, Lee GH, Kim JH, Yoon DH.
Scand J Gastroenterol. 2016 Aug;51(8):942-8. doi: 10.3109/00365521.2016.1151929. Epub 2016 May 5.
PMID: 27149022
103. [The clinical impact of thalidomide maintenance after autologous stem cell transplantation in patients with newly diagnosed multiple myeloma in real clinical practice of Korea.](#)
Lee HS, Min CK, Lee JJ, Kim K, Kim SJ, Yoon DH, Eom HS, Lee H, Lee WS, Shin HJ, Lee JH, Park Y, Jo JC, Do YR, Mun YC, Lee MH; Korean Multiple Myeloma Working Party (KMMWP).
Ann Hematol. 2016 May;95(6):911-9. doi: 10.1007/s00277-016-2660-8. Epub 2016 Apr 6.
PMID: 27052989
104. [Results of a phase II study of vorinostat in combination with intravenous fludarabine, mitoxantrone, and dexamethasone in patients with relapsed or refractory mantle cell lymphoma: an interim analysis.](#)
Shin DY, Kim SJ, Yoon DH, Park Y, Kong JH, Kim JA, Kim BS, Kim HJ, Won JH, Park SK, Kim WS.
Cancer Chemother Pharmacol. 2016 Apr;77(4):865-73. doi: 10.1007/s00280-016-3005-y. Epub 2016 Mar 16.
PMID: 26984211 Clinical Trial.
105. [Occurrence of sarcoidosis after chemotherapy for non-Hodgkin lymphoma.](#)
Cho H, Yoon DH, Kim JH, Ko YB, Kwon BS, Song IH, Suh C.
Korean J Intern Med. 2016 May;31(3):605-7. doi: 10.3904/kjim.2014.305. Epub 2016 Mar 12.
PMID: 26968186 Free PMC article. No abstract available.
106. [Pretreatment whole blood Epstein-Barr virus-DNA is a significant prognostic marker in patients with Hodgkin lymphoma.](#)
Park JH, Yoon DH, Kim S, Park JS, Park CS, Sung H, Lee SW, Huh J, Suh C.
Ann Hematol. 2016 Apr;95(5):801-8. doi: 10.1007/s00277-016-2610-5. Epub 2016 Feb 17.
PMID: 26883027
107. [A prognostic index for natural killer cell lymphoma after non-anthracycline-based treatment: a multicentre, retrospective analysis.](#)
Kim SJ, Yoon DH, Jaccard A, Chng WJ, Lim ST, Hong H, Park Y, Chang KM, Maeda Y, Ishida F, Shin DY, Kim JS, Jeong SH, Yang DH, Jo JC, Lee GW, Choi CW, Lee WS, Chen TY, Kim K, Jung SH, Murayama T, Oki Y, Advani R, d'Amore F, Schmitz N, Suh C, Suzuki R, Kwong YL, Lin TY, Kim WS.
Lancet Oncol. 2016 Mar;17(3):389-400. doi: 10.1016/S1470-2045(15)00533-1. Epub 2016 Feb 10.
PMID: 26873565
108. [A phase II study of everolimus \(RAD001\), an mTOR inhibitor plus CHOP for newly diagnosed peripheral T-cell lymphomas.](#)
Kim SJ, Shin DY, Kim JS, Yoon DH, Lee WS, Lee H, Do YR, Kang HJ, Eom HS, Ko YH, Lee SH, Yoo HY, Hong M, Suh C, Kim WS.
Ann Oncol. 2016 Apr;27(4):712-8. doi: 10.1093/annonc/mdv624. Epub 2016 Feb 8.
PMID: 26861608 Clinical Trial.
109. [Intraocular lymphoma in Korea: the Consortium for Improving Survival of Lymphoma \(CISL\) study.](#)
Lee S, Kim MJ, Kim JS, Oh SY, Kim SJ, Kwon YH, Chung IY, Kang JH, Yang DH, Kang HJ, Yoon DH, Kim WS, Kim HJ, Suh C.
Blood Res. 2015 Dec;50(4):242-7. doi: 10.5045/br.2015.50.4.242. Epub 2015 Dec 21.
PMID: 26770952 Free PMC article.
110. [Thin-Section CT Characteristics and Longitudinal CT Follow-up of Chemotherapy Induced Interstitial Pneumonitis: A Retrospective Cohort Study.](#)
Lee HN, Kim MY, Koo HJ, Kim SS, Yoon DH, Lee JC, Song JW.

- Medicine (Baltimore). 2016 Jan;95(2):e2460. doi: 10.1097/MD.0000000000002460. PMID: 26765442 Free PMC article.
111. [Prognostic factors for re-mobilization using plerixafor and granulocyte colony-stimulating factor \(G-CSF\) in patients with malignant lymphoma or multiple myeloma previously failing mobilization with G-CSF with or without chemotherapy: the Korean multicenter retrospective study.](#)
Kim JS, Yoon DH, Park S, Yoon SS, Cho SG, Min CK, Lee JJ, Yang DH, Kwak JY, Eom HS, Kim WS, Kim H, Do YR, Moon JH, Lee J, Suh C.
Ann Hematol. 2016 Mar;95(4):603-11. doi: 10.1007/s00277-016-2589-y. Epub 2016 Jan 11.
PMID: 26754633
 112. [Pneumocystis pneumonia versus rituximab-induced interstitial lung disease in lymphoma patients receiving rituximab-containing chemotherapy.](#)
Park SY, Kim MY, Choi WJ, Yoon DH, Lee SO, Choi SH, Kim YS, Suh C, Woo JH, Kim SH.
Med Mycol. 2017 Jun 1;55(4):349-357. doi: 10.1093/mmy/myw095.
PMID: 28339533
 113. [Programmed death 1 expression in the peritumoral microenvironment is associated with a poorer prognosis in classical Hodgkin lymphoma.](#)
Koh YW, Jeon YK, Yoon DH, Suh C, Huh J.
Tumour Biol. 2016 Jun;37(6):7507-14. doi: 10.1007/s13277-015-4622-5. Epub 2015 Dec 17.
PMID: 26678894
 114. [Engagement of CD99 Reduces AP-1 Activity by Inducing BATF in the Human Multiple Myeloma Cell Line RPMI8226.](#)
Gil M, Pak HK, Park SJ, Lee AN, Park YS, Lee H, Lee H, Kim KE, Lee KJ, Yoon DH, Chung YS, Park CS.
Immune Netw. 2015 Oct;15(5):260-7. doi: 10.4110/in.2015.15.5.260. Epub 2015 Oct 26.
PMID: 26557810 Free PMC article.
 115. [A phase II study of oxaliplatin and prednisone for patients with relapsed or refractory marginal zone lymphoma: Consortium for Improving Survival of Lymphoma trial.](#)
Oh SY, Kim WS, Kim JS, Chae YS, Lee GW, Eom HS, Ryoo HM, Lee S, Kim SJ, Yoon DH, Won JH, Hong J, Park J, Lee SM, Hong JY, Park E, Kim HJ, Yang DH, Kim HJ, Suh C.
Leuk Lymphoma. 2016;57(6):1406-12. doi: 10.3109/10428194.2015.1099650. Epub 2015 Nov 16.
PMID: 26413982 Clinical Trial.
 116. [The prognostic impact of inflammatory factors in patients with multiple myeloma treated with thalidomide in Korea.](#)
Kim C, Lee HS, Min CK, Lee JJ, Kim K, Yoon DH, Eom HS, Lee H, Lee WS, Shin HJ, Lee JH, Park Y, Jo JC, Do YR, Mun YC.
Korean J Intern Med. 2015 Sep;30(5):675-83. doi: 10.3904/kjim.2015.30.5.675. Epub 2015 Aug 28.
PMID: 26354062 Free PMC article.
 117. [Induction chemotherapy followed by up-front autologous stem cell transplantation may have a survival benefit in high-risk diffuse large B-cell lymphoma patients.](#)
Shin HJ, Yoon DH, Lee HS, Oh SY, Yang DH, Kang HJ, Chong SY, Park Y, Do Y, Lim SN, Jo JC, Lee WS, Chung JS; Consortium for Improving Survival of Lymphoma.
Exp Hematol. 2016 Jan;44(1):3-13. doi: 10.1016/j.exphem.2015.08.008. Epub 2015 Aug 29.
PMID: 26325332
 118. [A Randomized, Multicenter, Phase II Study of Cetuximab With Docetaxel and Cisplatin as Induction Chemotherapy in Unresectable, Locally Advanced Head and Neck Cancer.](#)
Lee KW, Koh Y, Kim SB, Shin SW, Kang JH, Wu HG, Sung MW, Keam B, Kim DW, Kim TM, Kim KH, Kwon TK, Hah JH, Kim IA, Ahn SH, Yoon DH, Lee SW, Kim SY, Nam SY, Jung KY, Baek SK, Hong SH, Lee SH, Heo DS.

- Oncologist. 2015 Oct;20(10):1119-20. doi: 10.1634/theoncologist.2015-0208. Epub 2015 Aug 24.
PMID: 26304911 Free PMC article. Clinical Trial.
119. [Is there role of additional chemotherapy after definitive local treatment for stage I/II marginal zone lymphoma?: Consortium for Improving Survival of Lymphoma \(CISL\) study.](#)
Koh MS, Kim WS, Kim SJ, Oh SY, Yoon DH, Lee SI, Hong J, Song MK, Shin HJ, Kwon JH, Kim HJ, Do YR, Suh C, Kim HJ.
Int J Hematol. 2015 Oct;102(4):420-5. doi: 10.1007/s12185-015-1845-6. Epub 2015 Jul 26.
PMID: 26210384 Clinical Trial.
120. [Body mass index as a prognostic factor in Asian patients treated with chemoimmunotherapy for diffuse large B cell lymphoma, not otherwise specified.](#)
Hwang HS, Yoon DH, Suh C, Huh J.
Ann Hematol. 2015 Oct;94(10):1655-65. doi: 10.1007/s00277-015-2438-4. Epub 2015 Jul 15.
PMID: 26174908
121. [Clinical Outcomes and Prognostic Factors of Up-Front Autologous Stem Cell Transplantation in Patients with Extranodal Natural Killer/T Cell Lymphoma.](#)
Yhim HY, Kim JS, Mun YC, Moon JH, Chae YS, Park Y, Jo JC, Kim SJ, Yoon DH, Cheong JW, Kwak JY, Lee JJ, Kim WS, Suh C, Yang DH; Consortium for Improving Survival of Lymphoma Study.
Biol Blood Marrow Transplant. 2015 Sep;21(9):1597-604. doi: 10.1016/j.bbmt.2015.05.003. Epub 2015 May 8.
PMID: 25963920 Clinical Trial.
122. [Insulin-like growth factor-1 receptor is associated with better prognosis in classical Hodgkin's lymphoma: Correlation with MET expression.](#)
Koh YW, Yoon DH, Suh C, Cha HJ, Huh J.
Int J Exp Pathol. 2015 Aug;96(4):232-9. doi: 10.1111/iep.12128. Epub 2015 Apr 27.
PMID: 25916750 Free PMC article.
123. [Phase 2 study of dovitinib in patients with metastatic or unresectable adenoid cystic carcinoma.](#)
Keam B, Kim SB, Shin SH, Cho BC, Lee KW, Kim MK, Yun HJ, Lee SH, Yoon DH, Bang YJ.
Cancer. 2015 Aug 1;121(15):2612-7. doi: 10.1002/cncr.29401. Epub 2015 Apr 22.
PMID: 25903089 Clinical Trial.
124. [Autophagic Markers BECLIN 1 and LC3 are Associated with Prognosis of Multiple Myeloma.](#)
Jung G, Roh J, Lee H, Gil M, Yoon DH, Suh C, Jang S, Park CJ, Huh J, Park CS.
Acta Haematol. 2015;134(1):17-24. doi: 10.1159/000368848. Epub 2015 Apr 3.
PMID: 25871810 Clinical Trial.
125. [Tau and PTEN status as predictive markers for response to trastuzumab and paclitaxel in patients with HER2-positive breast cancer.](#)
Koo DH, Lee HJ, Ahn JH, Yoon DH, Kim SB, Gong G, Son BH, Ahn SH, Jung KH.
Tumour Biol. 2015 Aug;36(8):5865-71. doi: 10.1007/s13277-015-3258-9. Epub 2015 Mar 1.
PMID: 25725586
126. [Serum beta-2 microglobulin as a prognostic biomarker in patients with mantle cell lymphoma.](#)
Yoo C, Yoon DH, Kim S, Huh J, Park CS, Park CJ, Lee SW, Suh C.
Hematol Oncol. 2016 Mar;34(1):22-7. doi: 10.1002/hon.2188. Epub 2015 Feb 16.
PMID: 25689467
127. [TCL1 expression predicts overall survival in patients with mantle cell lymphoma.](#)
Shin SJ, Roh J, Cha HJ, Choi YD, Kim JM, Min SK, Kim JE, Eom DW, Lee H, Kim HJ, Yoon DH, Suh C, Huh J.
Eur J Haematol. 2015 Dec;95(6):583-94. doi: 10.1111/ejh.12539. Epub 2015 Mar 16.

- PMID: 25688912
128. [Randomized phase 2 trial of S1 and oxaliplatin-based chemoradiotherapy with or without induction chemotherapy for esophageal cancer.](#)
Yoon DH, Jang G, Kim JH, Kim YH, Kim JY, Kim HR, Jung HY, Lee GH, Song HY, Cho KJ, Ryu JS, Kim SB.
Int J Radiat Oncol Biol Phys. 2015 Mar 1;91(3):489-96. doi: 10.1016/j.ijrobp.2014.11.019. Epub 2015 Jan 30.
PMID: 25680595 Clinical Trial.
 129. [A Case of Type II Enteropathy-Associated T-Cell Lymphoma with Epstein-Barr Virus Positivity.](#)
Song MJ, Park CS, Hwang HS, Suh CW, Yoon DH, Huh J.
Korean J Pathol. 2014 Dec;48(6):426-9. doi: 10.4132/KoreanJPathol.2014.48.6.426. Epub 2014 Dec 31.
PMID: 25588633 Free PMC article. No abstract available.
 130. [Prognostic effect of Ki-67 expression in rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone-treated diffuse large B-cell lymphoma is limited to non-germinal center B-cell-like subtype in late-elderly patients.](#)
Koh YW, Hwang HS, Park CS, Yoon DH, Suh C, Huh J.
Leuk Lymphoma. 2015;56(9):2630-6. doi: 10.3109/10428194.2015.1004169. Epub 2015 Feb 4.
PMID: 25573205
 131. [Case series of precursor B-cell lymphoblastic lymphoma.](#)
Kim JY, Om SY, Shin SJ, Kim JE, Yoon DH, Suh C.
Blood Res. 2014 Dec;49(4):270-4. doi: 10.5045/br.2014.49.4.270. Epub 2014 Dec 23.
PMID: 25548762 Free PMC article.
 132. [Clinical features and outcomes in patients with human immunodeficiency virus-negative, multicentric Castleman's disease: a single medical center experience.](#)
Seo S, Yoo C, Yoon DH, Kim S, Park JS, Park CS, Huh J, Suh C.
Blood Res. 2014 Dec;49(4):253-8. doi: 10.5045/br.2014.49.4.253. Epub 2014 Dec 23.
PMID: 25548759 Free PMC article.
 133. [Diffuse Large B-Cell Lymphoma with Involvement of the Breast and Testis in a Male Patient.](#)
Choi E, Jo JC, Yoon DH, Kim S, Lee K, Huh J, Park CS, Lee SW, Suh C.
Cancer Res Treat. 2015 Jul;47(3):539-43. doi: 10.4143/crt.2013.245. Epub 2014 Sep 11.
PMID: 25544585 Free PMC article.
 134. [Treatment Outcomes of Rituximab Plus Hyper-CVAD in Korean Patients with Sporadic Burkitt or Burkitt-like Lymphoma: Results of a Multicenter Analysis.](#)
Hong J, Kim SJ, Ahn JS, Song MK, Kim YR, Lee HS, Yhim HY, Yoon DH, Kim MK, Oh SY, Park Y, Mun YC, Do YR, Ryoo HM, Lee JJ, Lee JH, Kim WS, Suh C.
Cancer Res Treat. 2015 Apr;47(2):173-81. doi: 10.4143/crt.2014.055. Epub 2014 Oct 28.
PMID: 25544581 Free PMC article.
 135. [EBV-positive diffuse large B-cell lymphoma in young adults: is this a distinct disease entity?](#)
Hong JY, Yoon DH, Suh C, Huh J, Do IG, Sohn I, Jo J, Jung SH, Hong ME, Yoon H, Ko YH, Kim SJ, Kim WS.
Ann Oncol. 2015 Mar;26(3):548-55. doi: 10.1093/annonc/mdu556. Epub 2014 Dec 4.
PMID: 25475080 Clinical Trial.
 136. [Primary histiocytic sarcoma of the central nervous system.](#)
So H, Kim SA, Yoon DH, Khang SK, Hwang J, Suh CH, Suh C.
Cancer Res Treat. 2015 Apr;47(2):322-8. doi: 10.4143/crt.2013.163. Epub 2014 Aug 29.
PMID: 25345462 Free PMC article.
 137. [Treatment of primary testicular diffuse large B cell lymphoma without prophylactic intrathecal chemotherapy: a single center experience.](#)
Kim J, Yoon DH, Park I, Kim S, Park JS, Lee SW, Huh J, Park CS, Suh C.
Blood Res. 2014 Sep;49(3):170-6. doi: 10.5045/br.2014.49.3.170. Epub 2014 Sep 25.

- PMID: 25325036 Free PMC article.
138. [Serum beta-2 microglobulin in malignant lymphomas: an old but powerful prognostic factor.](#)
Yoo C, Yoon DH, Suh C.
Blood Res. 2014 Sep;49(3):148-53. doi: 10.5045/br.2014.49.3.148. Epub 2014 Sep 25.
PMID: 25325033 Free PMC article. Review.
 139. [The absolute lymphocyte to monocyte ratio is associated with poor prognosis in classical Hodgkin lymphoma patients younger than 60 years of age.](#)
Koh YW, Jung SJ, Yoon DH, Suh C, Cha HJ, Go H, Kim JE, Kim CW, Huh J.
Hematol Oncol. 2015 Sep;33(3):133-40. doi: 10.1002/hon.2155. Epub 2014 Sep 16.
PMID: 25224646
 140. [Non-surgical treatment versus radical esophagectomy for clinical T1N0M0 esophageal carcinoma: a single-center experience.](#)
Park I, Kim YH, Yoon DH, Park SR, Kim HR, Kim JH, Jung HY, Lee GH, Cho KJ, Kim SB.
Cancer Chemother Pharmacol. 2014 Nov;74(5):995-1003. doi: 10.1007/s00280-014-2573-y. Epub 2014 Sep 5.
PMID: 25190176
 141. [The highest prognostic impact of LDH among International Prognostic Indices \(IPIs\): an explorative study of five IPI factors among patients with DLBCL in the era of rituximab.](#)
Park JH, Yoon DH, Kim DY, Kim S, Seo S, Jeong Y, Lee SW, Park CS, Huh J, Suh C.
Ann Hematol. 2014 Oct;93(10):1755-64. doi: 10.1007/s00277-014-2115-z. Epub 2014 Jul 16.
PMID: 25027115
 142. [Abbreviated chemotherapy for limited-stage diffuse large B-cell lymphoma after complete resection.](#)
Jo J, Yoon DH, Lee SW, Park CS, Huh J, Lee K, Kang EH, Kim S, Suh C.
Blood Res. 2014 Jun;49(2):115-9. doi: 10.5045/br.2014.49.2.115. Epub 2014 Jun 25.
PMID: 25025013 Free PMC article.
 143. [Expression of CD99 in Multiple Myeloma: A Clinicopathologic and Immunohistochemical Study of 170 Cases.](#)
Shin SJ, Lee H, Jung G, Gil M, Park H, Park YS, Yoon DH, Suh C, Park CJ, Huh J, Park CS.
Korean J Pathol. 2014 Jun;48(3):209-16. doi: 10.4132/KoreanJPathol.2014.48.3.209. Epub 2014 Jun 26.
PMID: 25013419 Free PMC article.
 144. [Clinical factors associated with response or survival after chemotherapy in patients with Waldenström macroglobulinemia in Korea.](#)
Lee HS, Kim K, Yoon DH, Kim JS, Bang SM, Lee JO, Eom HS, Lee H, Kim I, Lee WS, Bae SH, Kim SH, Lee MH, Do YR, Lee JH, Hong J, Shin HJ, Lee JH, Mun YC, Min CK.
Biomed Res Int. 2014;2014:253243. doi: 10.1155/2014/253243. Epub 2014 Jun 4.
PMID: 24995279 Free PMC article.
 145. [Absolute monocyte count predicts overall survival in mantle cell lymphomas: correlation with tumour-associated macrophages.](#)
Koh YW, Shin SJ, Park C, Yoon DH, Suh C, Huh J.
Hematol Oncol. 2014 Dec;32(4):178-86. doi: 10.1002/hon.2106. Epub 2013 Oct 29.
PMID: 24910369
 146. [\(18\)F-FDG PET in Patients with Primary Systemic Anaplastic Large Cell Lymphoma: Differential Features According to Expression of Anaplastic Lymphoma Kinase.](#)
Lee DY, Lee JJ, Kim JY, Park SH, Chae SY, Kim S, Yoon DH, Suh C, Huh J, Ryu JS.
Nucl Med Mol Imaging. 2013 Dec;47(4):249-56. doi: 10.1007/s13139-013-0224-6. Epub 2013 Aug 23.
PMID: 24900120 Free PMC article.
 147. [Advanced POEMS syndrome treated with high-dose melphalan followed by autologous blood stem cell transplantation: a single-center experience.](#)
Jang IY, Yoon DH, Kim S, Lee K, Kim KK, Lim YM, Min WK, Suh C.

- Blood Res. 2014 Mar;49(1):42-8. doi: 10.5045/br.2014.49.1.42. Epub 2014 Mar 24. PMID: 24724066 Free PMC article.
148. [Primary mediastinal large B-cell lymphoma: a single-center experience in Korea.](#)
Ahn HJ, Yoon DH, Kim S, Lee K, Kang E, Huh J, Park CS, Suh C.
Blood Res. 2014 Mar;49(1):36-41. doi: 10.5045/br.2014.49.1.36. Epub 2014 Mar 24. PMID: 24724065 Free PMC article.
 149. [High concordance of gene expression profiling-correlated immunohistochemistry algorithms in diffuse large B-cell lymphoma, not otherwise specified.](#)
Hwang HS, Park CS, Yoon DH, Suh C, Huh J.
Am J Surg Pathol. 2014 Aug;38(8):1046-57. doi: 10.1097/PAS.0000000000000211. PMID: 24705314
 150. [CSF-1R expression in tumor-associated macrophages is associated with worse prognosis in classical Hodgkin lymphoma.](#)
Koh YW, Park C, Yoon DH, Suh C, Huh J.
Am J Clin Pathol. 2014 Apr;141(4):573-83. doi: 10.1309/AJCPR92TDDFARISU. PMID: 24619759
 151. [LGALS3 as a prognostic factor for classical Hodgkin's lymphoma.](#)
Koh YW, Jung SJ, Park CS, Yoon DH, Suh C, Huh J.
Mod Pathol. 2014 Oct;27(10):1338-44. doi: 10.1038/modpathol.2014.38. Epub 2014 Mar 7. PMID: 24603587
 152. [CD163 expression was associated with angiogenesis and shortened survival in patients with uniformly treated classical Hodgkin lymphoma.](#)
Koh YW, Park CS, Yoon DH, Suh C, Huh J.
PLoS One. 2014 Jan 29;9(1):e87066. doi: 10.1371/journal.pone.0087066. eCollection 2014. PMID: 24489836 Free PMC article.
 153. [Prognostic value of immunohistochemical algorithms in gastrointestinal diffuse large B-cell lymphoma.](#)
Hwang HS, Yoon DH, Suh C, Park CS, Huh J.
Blood Res. 2013 Dec;48(4):266-73. doi: 10.5045/br.2013.48.4.266. Epub 2013 Dec 24. PMID: 24466551 Free PMC article.
 154. [Prognostic impact of beta-2 microglobulin in patients with extranodal natural killer/T cell lymphoma.](#)
Yoo C, Yoon DH, Jo JC, Yoon S, Kim S, Lee BJ, Huh J, Lee SW, Suh C.
Ann Hematol. 2014 Jun;93(6):995-1000. doi: 10.1007/s00277-014-2015-2. Epub 2014 Jan 19. PMID: 24441948
 155. [Intestinal diffuse large B-cell lymphoma: an evaluation of different staging systems.](#)
Hwang HS, Yoon DH, Suh C, Park CS, Huh J.
J Korean Med Sci. 2014 Jan;29(1):53-60. doi: 10.3346/jkms.2014.29.1.53. Epub 2013 Dec 26. PMID: 24431906 Free PMC article.
 156. [Prognostic significance of absolute lymphocyte count/absolute monocyte count ratio at diagnosis in patients with multiple myeloma.](#)
Shin SJ, Roh J, Kim M, Jung MJ, Koh YW, Park CS, Yoon DH, Suh C, Park CJ, Chi HS, Huh J.
Korean J Pathol. 2013 Dec;47(6):526-33. doi: 10.4132/KoreanJPathol.2013.47.6.526. Epub 2013 Dec 24. PMID: 24421845 Free PMC article.
 157. [Importance of FOXP3 in prognosis and its relationship with p16 in tonsillar squamous cell carcinoma.](#)
Park K, Cho KJ, Lee M, Yoon DH, Kim SB.
Anticancer Res. 2013 Dec;33(12):5667-73. PMID: 24324115

158. [Role of surgical resection in complete responders on FDG-PET after chemoradiotherapy for locally advanced esophageal squamous cell carcinoma.](#)
Jeong Y, Kim JH, Kim SB, Yoon DH, Park SI, Kim YH, Kim HR, Jung HY, Lee GH, Ryu JS. J Surg Oncol. 2014 Apr;109(5):472-7. doi: 10.1002/jso.23514. Epub 2013 Dec 2. PMID: 24301552
159. [Clinical significance of the appearance of abnormal protein band in patients with multiple myeloma.](#)
Jo JC, Yoon DH, Kim S, Lee K, Kang EH, Jang S, Park CJ, Chi HS, Huh J, Park CS, Suh C. Ann Hematol. 2014 Mar;93(3):463-9. doi: 10.1007/s00277-013-1890-2. Epub 2013 Sep 3. PMID: 23999647
160. [Prognostic significance of COX-2 expression and correlation with Bcl-2 and VEGF expression, microvessel density, and clinical variables in classical Hodgkin lymphoma.](#)
Koh YW, Park C, Yoon DH, Suh C, Huh J. Am J Surg Pathol. 2013 Aug;37(8):1242-51. doi: 10.1097/PAS.0b013e31828b6ad3. PMID: 23851330
161. [Chemotherapy-induced amenorrhea, menopause-specific quality of life, and endocrine profiles in premenopausal women with breast cancer who received adjuvant anthracycline-based chemotherapy: a prospective cohort study.](#)
Yoo C, Yun MR, Ahn JH, Jung KH, Kim HJ, Kim JE, Park JY, Park KO, Yoon DH, Kim SB. Cancer Chemother Pharmacol. 2013 Sep;72(3):565-75. doi: 10.1007/s00280-013-2227-5. Epub 2013 Jul 11. PMID: 23842722 Clinical Trial.
162. [Changing trend of Epstein-Barr virus association in Hodgkin lymphoma in the Republic of Korea.](#)
Koh YW, Kang HJ, Yoon DH, Suh C, Kim JE, Kim CW, Huh J. Ann Hematol. 2013 Dec;92(12):1653-60. doi: 10.1007/s00277-013-1837-7. Epub 2013 Jul 6. PMID: 23832190 Review.
163. [Remobilization of hematopoietic stem cells with high-dose methotrexate and cytarabine in patients with non-Hodgkin's lymphoma and multiple myeloma after failure to mobilize with chemotherapy and cytokines.](#)
Park SJ, Yoon DH, Kim S, Lee K, Park JS, Jang S, Park CJ, Chi HS, Park CS, Huh J, Suh C. Transfusion. 2014 Mar;54(3):509-15. doi: 10.1111/trf.12314. Epub 2013 Jun 26. PMID: 23800093
164. [Receptor tyrosine kinases MET and RON as prognostic factors in diffuse large B-cell lymphoma patients receiving R-CHOP.](#)
Koh YW, Hwang HS, Jung SJ, Park C, Yoon DH, Suh C, Huh J. Cancer Sci. 2013 Sep;104(9):1245-51. doi: 10.1111/cas.12215. Epub 2013 Jul 11. PMID: 23745832 Free PMC article.
165. [The role of ¹⁸F-fluorodeoxyglucose positron emission tomography at response assessment after autologous stem cell transplantation in T-cell non-Hodgkin's lymphoma patients.](#)
Sohn BS, Yoon DH, Kim KP, Kim S, Lee KM, Park JS, Lee DH, Ryu JS, Huh J, Hong IK, Suh C. Ann Hematol. 2013 Oct;92(10):1369-77. doi: 10.1007/s00277-013-1782-5. Epub 2013 May 21. PMID: 23689845
166. [Immunophenotypic characterization and quantification of neoplastic bone marrow plasma cells by multiparametric flow cytometry and its clinical significance in Korean myeloma patients.](#)
Cho YU, Park CJ, Park SJ, Chi HS, Jang S, Park SH, Seo EJ, Yoon DH, Lee JH, Suh C. J Korean Med Sci. 2013 Apr;28(4):542-9. doi: 10.3346/jkms.2013.28.4.542. Epub 2013 Mar 27. PMID: 23580331 Free PMC article.

167. [Can concurrent chemoradiotherapy replace surgery and postoperative radiation for locally advanced stage III/IV tonsillar squamous cell carcinoma?](#)
Park G, Lee SW, Kim SY, Nam SY, Choi SH, Kim SB, Roh JL, Yoon DH, Kim SS, Park JH, Kim YS, Yoon SM, Song SY, Kim JH, Choi EK, DO Ahn S.
Anticancer Res. 2013 Mar;33(3):1237-43.
PMID: 23482808
168. [Clinical characteristics and prognostic factors of adenoid cystic carcinoma of the head and neck.](#)
Choi Y, Kim SB, Yoon DH, Kim JY, Lee SW, Cho KJ.
Laryngoscope. 2013 Jun;123(6):1430-8. doi: 10.1002/lary.23976. Epub 2013 Feb 16.
PMID: 23417869
169. [Prognostic implications of tumor extent in early-stage diffuse large B-cell lymphoma.](#)
Yoo C, Yoon DH, Kim JE, Jo J, Park SJ, Yoon SK, Ahn Y, Kim S, Huh J, Lee DH, Suh C.
Int J Hematol. 2013 Feb;97(2):232-9. doi: 10.1007/s12185-013-1260-9. Epub 2013 Jan 29.
PMID: 23359300
170. [High-dose chemotherapy and autologous stem-cell transplantation in Korean patients with relapsed or refractory Hodgkin lymphoma.](#)
Park K, Yoon DH, Kim S, Park CS, Huh J, Lee SW, Suh C.
Int J Hematol. 2013 Feb;97(2):256-62. doi: 10.1007/s12185-013-1267-2. Epub 2013 Jan 26.
PMID: 23355263
171. [Subtle CD20 positivity in the bone marrow of a patient who has a mucosa-associated lymphoid tissue lymphoma should not be regarded as evidence of involvement in the bone marrow.](#)
Won D, Park CJ, Shim H, Jang S, Chi HS, Huh J, Yoon DH, Suh C.
Histopathology. 2013 Feb;62(3):397-405. doi: 10.1111/his.12005. Epub 2012 Nov 16.
PMID: 23163529
172. [Prognostic significance of the ratio of absolute neutrophil count to absolute lymphocyte count in classic Hodgkin lymphoma.](#)
Koh YW, Kang HJ, Park C, Yoon DH, Kim S, Suh C, Kim JE, Kim CW, Huh J.
Am J Clin Pathol. 2012 Dec;138(6):846-54. doi: 10.1309/AJCPO46GFKGNXCBR.
PMID: 23161719
173. [Blastic plasmacytoid dendritic cell neoplasm: a single-center experience.](#)
An HJ, Yoon DH, Kim S, Shin SJ, Huh J, Lee KH, Suh C.
Ann Hematol. 2013 Mar;92(3):351-6. doi: 10.1007/s00277-012-1614-z. Epub 2012 Nov 8.
PMID: 23135479
174. [p16 immunohistochemistry alone is a better prognosticator in tonsil cancer than human papillomavirus in situ hybridization with or without p16 immunohistochemistry.](#)
Park K, Cho KJ, Lee M, Yoon DH, Kim J, Kim SY, Nam SY, Choi SH, Roh JL, Han MW, Lee SW, Song SY, Back JH, Kim SB.
Acta Otolaryngol. 2013 Mar;133(3):297-304. doi: 10.3109/00016489.2012.741327. Epub 2012 Nov 6.
PMID: 23130632
175. [Point prevalence of Pneumocystis pneumonia in patients with non-Hodgkin lymphoma according to the number of cycles of R-CHOP chemotherapy.](#)
Kim T, Choi SH, Kim SH, Jeong JY, Woo JH, Kim YS, Sung H, Kim MN, Yoon DH, Suh C, Lee SO.
Ann Hematol. 2013 Jan;92(2):231-8. doi: 10.1007/s00277-012-1592-1. Epub 2012 Oct 10.
PMID: 23053189 Free PMC article.
176. [Salvage esophagectomy for locoregional failure after chemoradiotherapy in patients with advanced esophageal cancer.](#)
Yoo C, Park JH, Yoon DH, Park SI, Kim HR, Kim JH, Jung HY, Lee GH, Choi KD, Song HJ, Song HY, Shin JH, Cho KJ, Kim YH, Kim SB.
Ann Thorac Surg. 2012 Dec;94(6):1862-8. doi: 10.1016/j.athoracsur.2012.07.042. Epub

- 2012 Sep 7.
PMID: 22959577
177. [A unique pattern of extranodal involvement in Korean adults with sporadic Burkitt lymphoma: a single center experience.](#)
Jang SJ, Yoon DH, Kim S, Yoon S, Kim DY, Park CS, Huh J, Lee SW, Lee DH, Ryu JS, Suh C.
Ann Hematol. 2012 Dec;91(12):1917-22. doi: 10.1007/s00277-012-1531-1. Epub 2012 Aug 5.
PMID: 22864762
 178. [The role of integrated 18F-FDG PET-CT as a staging tool for limited-stage small cell lung cancer: a retrospective study.](#)
Sohn BS, Lee DH, Kim EK, Yoon DH, Kim HO, Ryu JS, Kim SW, Suh C.
Onkologie. 2012;35(7-8):432-8. doi: 10.1159/000341073. Epub 2012 Jul 3.
PMID: 22846975
 179. [Impact of triple-negative breast cancer phenotype on prognosis in patients with stage I breast cancer.](#)
Kim JE, Ahn HJ, Ahn JH, Yoon DH, Kim SB, Jung KH, Gong GY, Kim MJ, Son BH, Ahn SH.
J Breast Cancer. 2012 Jun;15(2):197-202. doi: 10.4048/jbc.2012.15.2.197. Epub 2012 Jun 28.
PMID: 22807937 Free PMC article.
 180. [Relapse pattern and prognostic factors for patients with primary CNS lymphoma.](#)
Suh C, Kim JE, Yoon DH.
Korean J Hematol. 2012 Jun;47(2):155-6. doi: 10.5045/kjh.2012.47.2.155. Epub 2012 Jun 26.
PMID: 22783366 Free PMC article. No abstract available.
 181. [Yttrium-90 ibritumomab tiuxetan plus busulfan, cyclophosphamide, and etoposide \(BuCyE\) versus BuCyE alone as a conditioning regimen for non-Hodgkin lymphoma.](#)
Jo JC, Yoon DH, Kim S, Park JS, Park CS, Huh J, Lee SW, Ryu JS, Suh C.
Korean J Hematol. 2012 Jun;47(2):119-25. doi: 10.5045/kjh.2012.47.2.119. Epub 2012 Jun 26.
PMID: 22783358 Free PMC article.
 182. [The comparison between CHOP and R-CHOP in primary gastric diffuse large B cell lymphoma.](#)
Sohn BS, Kim SM, Yoon DH, Kim S, Lee DH, Kim JH, Lee SW, Huh J, Suh C.
Ann Hematol. 2012 Nov;91(11):1731-9. doi: 10.1007/s00277-012-1512-4. Epub 2012 Jul 3.
PMID: 22752193
 183. [The survivin suppressant YM155 potentiates chemosensitivity to gemcitabine in the human pancreatic cancer cell line MiaPaCa-2.](#)
Yoon DH, Shin JS, Jin DH, Hong SW, Jung KA, Kim SM, Hong YS, Kim KP, Lee JL, Suh C, Lee JS, Kim TW.
Anticancer Res. 2012 May;32(5):1681-8.
PMID: 22593446
 184. [The ratio of the absolute lymphocyte count to the absolute monocyte count is associated with prognosis in Hodgkin's lymphoma: correlation with tumor-associated macrophages.](#)
Koh YW, Kang HJ, Park C, Yoon DH, Kim S, Suh C, Go H, Kim JE, Kim CW, Huh J.
Oncologist. 2012;17(6):871-80. doi: 10.1634/theoncologist.2012-0034. Epub 2012 May 15.
PMID: 22588324 Free PMC article.
 185. [Clinical features and prognostic model for extranasal NK/T-cell lymphoma.](#)
Jo JC, Yoon DH, Kim S, Lee BJ, Jang YJ, Park CS, Huh J, Lee SW, Ryu JS, Suh C.
Eur J Haematol. 2012 Aug;89(2):103-10. doi: 10.1111/j.1600-0609.2012.01796.x.
PMID: 22553935
 186. [Bortezomib induces G2-M arrest in human colon cancer cells through ROS-inducible phosphorylation of ATM-CHK1.](#)

- Hong YS, Hong SW, Kim SM, Jin DH, Shin JS, Yoon DH, Kim KP, Lee JL, Heo DS, Lee JS, Kim TW.
 Int J Oncol. 2012 Jul;41(1):76-82. doi: 10.3892/ijo.2012.1448. Epub 2012 Apr 26.
 PMID: 22552540
187. [Extranodal natural killer/T-cell lymphoma from skin or soft tissue: suggestion of treatment from multinational retrospective analysis.](#)
 Ahn HK, Suh C, Chuang SS, Suzumiya J, Ko YH, Kim SJ, Huh JR, Yoon DH, Oh SY, Kim JS, Lee SI, Park KW, Hsieh PP, Nakamura S, Yoshino T, Ito K, Nagatani T, Oshimi K, Suzuki R, Kim WS.
 Ann Oncol. 2012 Oct;23(10):2703-2707. doi: 10.1093/annonc/mds096. Epub 2012 Apr 29.
 PMID: 22547542
188. [Increment of hematopoietic progenitor cell count as an indicator of efficient autologous stem cell harvest in patients with multiple myeloma.](#)
 Jo JC, Yoon DH, Kim S, Jang S, Park CJ, Chi HS, Park CS, Huh J, Lee SW, Suh C.
 J Clin Apher. 2012 Nov;27(5):229-34. doi: 10.1002/jca.21231. Epub 2012 Apr 25.
 PMID: 22535685
189. [Impact of the Epstein-Barr virus positivity on Hodgkin's lymphoma in a large cohort from a single institute in Korea.](#)
 Koh YW, Yoon DH, Suh C, Huh J.
 Ann Hematol. 2012 Sep;91(9):1403-12. doi: 10.1007/s00277-012-1464-8. Epub 2012 Apr 18.
 PMID: 22526365
190. [Relapse pattern and prognostic factors for patients with primary central nervous system lymphoma.](#)
 Kim JE, Yoon DH, Kim S, Lee DH, Kim JH, Yoon YH, Chi HS, Lee SW, Park CS, Huh J, Suh C.
 Korean J Hematol. 2012 Mar;47(1):60-6. doi: 10.5045/kjh.2012.47.1.60. Epub 2012 Mar 28.
 PMID: 22479279 Free PMC article.
191. [A phase I/II study of bortezomib plus CHOP every 2 weeks \(CHOP-14\) in patients with advanced-stage diffuse large B-cell lymphomas.](#)
 Kim JE, Yoon DH, Jang G, Lee DH, Kim S, Park CS, Huh J, Kim WS, Park J, Lee JH, Lee SI, Suh C.
 Korean J Hematol. 2012 Mar;47(1):53-9. doi: 10.5045/kjh.2012.47.1.53. Epub 2012 Mar 28.
 PMID: 22479278 Free PMC article.
192. [Phase II study of everolimus with biomarker exploration in patients with advanced gastric cancer refractory to chemotherapy including fluoropyrimidine and platinum.](#)
 Yoon DH, Ryu MH, Park YS, Lee HJ, Lee C, Ryoo BY, Lee JL, Chang HM, Kim TW, Kang YK.
 Br J Cancer. 2012 Mar 13;106(6):1039-44. doi: 10.1038/bjc.2012.47. Epub 2012 Feb 16.
 PMID: 22343617 Free PMC article. Clinical Trial.
193. [Prospective evaluation of the drug-metabolizing enzyme polymorphisms and toxicity profile of docetaxel in Korean patients with operable lymph node-positive breast cancer receiving adjuvant chemotherapy.](#)
 Kim KP, Ahn JH, Kim SB, Jung KH, Yoon DH, Lee JS, Ahn SH.
 Cancer Chemother Pharmacol. 2012 May;69(5):1221-7. doi: 10.1007/s00280-011-1816-4. Epub 2012 Jan 20.
 PMID: 22271208 Clinical Trial.
194. [The role of prophylactic antimicrobials during autologous stem cell transplantation: a single-center experience.](#)
 Sohn BS, Yoon DH, Kim S, Lee K, Kang EH, Park JS, Lee DH, Kim SH, Huh J, Suh C.
 Eur J Clin Microbiol Infect Dis. 2012 Jul;31(7):1653-61. doi: 10.1007/s10096-011-1489-2. Epub 2011 Dec 4.
 PMID: 22138805

195. [CD68 and CD163 as prognostic factors for Korean patients with Hodgkin lymphoma.](#)
Yoon DH, Koh YW, Kang HJ, Kim S, Park CS, Lee SW, Suh C, Huh J.
Eur J Haematol. 2012 Apr;88(4):292-305. doi: 10.1111/j.1600-0609.2011.01731.x. Epub 2011 Nov 24.
PMID: 22044760
196. [Translation and validation of Korean Functional Assessment of Cancer Therapy-Esophageal \(FACT-E\) scale with squamous cell carcinoma and chemoradiation-only patients.](#)
Yoo HJ, Kim SB, Yoon DH, Park SI, Kim JH, Cella D, Jung HY, Lee GH, Choi KD, Song HJ, Song HY, Shin JH, Cho KJ.
Qual Life Res. 2012 Oct;21(8):1451-7. doi: 10.1007/s11136-011-0050-1. Epub 2011 Nov 1.
PMID: 22042445
197. [Phase II study of use of a single cycle of induction chemotherapy and concurrent chemoradiotherapy containing capecitabine/cisplatin followed by surgery for patients with resectable esophageal squamous cell carcinoma: long-term follow-up data.](#)
Koo DH, Park SI, Kim YH, Kim JH, Jung HY, Lee GH, Choi KD, Song HJ, Song HY, Shin JH, Cho KJ, Yoon DH, Kim SB.
Cancer Chemother Pharmacol. 2012 Mar;69(3):655-63. doi: 10.1007/s00280-011-1750-5. Epub 2011 Oct 4.
PMID: 21968953 Clinical Trial.
198. [Addition of rituximab to the CHOP regimen has no benefit in patients with primary extranodal diffuse large B-cell lymphoma.](#)
Jang G, Yoon DH, Kim S, Lee DH, Lee SW, Huh J, Suh C.
Korean J Hematol. 2011 Jun;46(2):103-10. doi: 10.5045/kjh.2011.46.2.103. Epub 2011 Jun 21.
PMID: 21747882 Free PMC article.
199. [p34 \(SEI-1\) inhibits ROS-induced cell death through suppression of ASK1.](#)
Hong SW, Shin JS, Lee YM, Kim DG, Lee SY, Yoon DH, Jung SY, Hwang JJ, Lee SJ, Cho DH, Hong YS, Kim TW, Jin DH, Lee WK.
Cancer Biol Ther. 2011 Sep 1;12(5):421-6. doi: 10.4161/cbt.12.5.15972. Epub 2011 Sep 1.
PMID: 21725208
200. [FDG-PET as a potential tool for selecting patients with advanced non-small cell lung cancer who may be spared maintenance therapy after first-line chemotherapy.](#)
Yoon DH, Baek S, Choi CM, Lee DH, Suh C, Ryu JS, Moon DH, Lee JS, Kim SW.
Clin Cancer Res. 2011 Aug 1;17(15):5093-100. doi: 10.1158/1078-0432.CCR-10-2791. Epub 2011 Jun 14.
PMID: 21673067 Clinical Trial.
201. [Limited role of interim PET/CT in patients with diffuse large B-cell lymphoma treated with R-CHOP.](#)
Yoo C, Lee DH, Kim JE, Jo J, Yoon DH, Sohn BS, Kim SW, Lee JS, Suh C.
Ann Hematol. 2011 Jul;90(7):797-802. doi: 10.1007/s00277-010-1135-6. Epub 2010 Dec 22.
PMID: 21181163
202. [Sunitinib as a second-line therapy for advanced GISTs after failure of imatinib: relationship between efficacy and tumor genotype in Korean patients.](#)
Yoon DH, Ryu MH, Ryoo BY, Beck M, Choi DR, Cho Y, Lee JL, Chang HM, Kim TW, Kang YK.
Invest New Drugs. 2012 Apr;30(2):819-27. doi: 10.1007/s10637-010-9593-1. Epub 2010 Nov 23.
PMID: 21104107
203. [Modified number of extranodal involved sites as a prognosticator in R-CHOP-treated patients with disseminated diffuse large B-cell lymphoma.](#)
Yoo C, Kim S, Sohn BS, Kim JE, Yoon DH, Huh J, Lee DH, Kim SW, Lee JS, Suh C.
Korean J Intern Med. 2010 Sep;25(3):301-8. doi: 10.3904/kjim.2010.25.3.301. Epub 2010 Aug 31.
PMID: 20830228 Free PMC article.

204. [Usefulness of interim FDG-PET after induction chemotherapy in patients with locally advanced squamous cell carcinoma of the head and neck receiving sequential induction chemotherapy followed by concurrent chemoradiotherapy.](#)
Yoon DH, Cho Y, Kim SY, Nam SY, Choi SH, Roh JL, Lee SW, Song SY, Lee JH, Kim JS, Cho KJ, Kim SB.
Int J Radiat Oncol Biol Phys. 2011 Sep 1;81(1):118-25. doi: 10.1016/j.ijrobp.2010.04.034. Epub 2010 Aug 2.
PMID: 20675065
205. [Pyridoxine is not effective to prevent hand-foot syndrome associated with capecitabine therapy: results of a randomized, double-blind, placebo-controlled study.](#)
Kang YK, Lee SS, Yoon DH, Lee SY, Chun YJ, Kim MS, Ryu MH, Chang HM, Lee JL, Kim TW.
J Clin Oncol. 2010 Aug 20;28(24):3824-9. doi: 10.1200/JCO.2010.29.1807. Epub 2010 Jul 12.
PMID: 20625131 Clinical Trial.
206. [Sorafenib for recurrent hepatocellular carcinoma after liver transplantation.](#)
Yoon DH, Ryoo BY, Ryu MH, Lee SG, Hwang S, Suh DJ, Lee HC, Kim TW, Ahn CS, Kim KH, Moon DB, Kang YK.
Jpn J Clin Oncol. 2010 Aug;40(8):768-73. doi: 10.1093/jjco/hyq055. Epub 2010 May 21.
PMID: 20494947
207. [Ki-67 expression as a prognostic factor in diffuse large B-cell lymphoma patients treated with rituximab plus CHOP.](#)
Yoon DH, Choi DR, Ahn HJ, Kim S, Lee DH, Kim SW, Park BH, Yoon SO, Huh J, Lee SW, Suh C.
Eur J Haematol. 2010 Aug;85(2):149-57. doi: 10.1111/j.1600-0609.2010.01467.x. Epub 2010 May 6.
PMID: 20477862
208. [S-1 plus cisplatin: another option in the treatment of advanced head and neck cancer?](#)
Yoon DH, Kim SB.
Expert Rev Anticancer Ther. 2010 May;10(5):659-62. doi: 10.1586/era.10.45.
PMID: 20469998 Review.
209. [Metastasectomy for hepatic metastases from adenoid cystic carcinoma of the trachea.](#)
Park I, Lim SN, Yoon DH, Park H, Sun B, Lee PH, Hwang I, Lee DH.
Gut Liver. 2009 Jun;3(2):127-9. doi: 10.5009/gnl.2009.3.2.127. Epub 2009 Jun 30.
PMID: 20431735 Free PMC article.
210. [Feasibility of BU, CY and etoposide \(BUCYE\), and auto-SCT in patients with newly diagnosed primary CNS lymphoma: a single-center experience.](#)
Yoon DH, Lee DH, Choi DR, Sohn BS, Kim S, Kim SW, Lee JS, Lee SW, Huh J, Suh C.
Bone Marrow Transplant. 2011 Jan;46(1):105-9. doi: 10.1038/bmt.2010.71. Epub 2010 Apr 12.
PMID: 20383213 Clinical Trial.
211. [A phase I study of S-1 treatment with a 3 week schedule in advanced biliary cancer patients with or without hepatic dysfunction.](#)
Yoon DH, Lee HJ, Hong YS, Kim KP, Lee SS, Lee JL, Chang HM, Ryu MH, Kang YK, Lee JS, Kim TW.
Invest New Drugs. 2011 Apr;29(2):332-9. doi: 10.1007/s10637-009-9378-6. Epub 2009 Dec 30.
PMID: 20041339 Clinical Trial.
212. [Percutaneous management of a bronchobiliary fistula after radiofrequency ablation in a patient with hepatocellular carcinoma.](#)
Yoon DH, Shim JH, Lee WJ, Kim PN, Shin JH, Kim KM.
Korean J Radiol. 2009 Jul-Aug;10(4):411-5. doi: 10.3348/kjr.2009.10.4.411. Epub 2009 Jun 25.
PMID: 19568472 Free PMC article.
213. [A case of primary adrenal diffuse large B-cell lymphoma achieving complete remission](#)

- [with rituximab-CHOP chemotherapy.](#)
Kim KM, Yoon DH, Lee SG, Lim SN, Sug LJ, Huh J, Suh C.
J Korean Med Sci. 2009 Jun;24(3):525-8. doi: 10.3346/jkms.2009.24.3.525. Epub 2009 Jun 16.
PMID: 19543522 Free PMC article.
214. [Higher infused CD34+ hematopoietic stem cell dose correlates with earlier lymphocyte recovery and better clinical outcome after autologous stem cell transplantation in non-Hodgkin's lymphoma.](#)
Yoon DH, Sohn BS, Jang G, Kim EK, Kang BW, Kim C, Kim JE, Kim S, Lee DH, Lee JS, Park SJ, Park CJ, Huh J, Suh C.
Transfusion. 2009 Sep;49(9):1890-900. doi: 10.1111/j.1537-2995.2009.02202.x. Epub 2009 May 11.
PMID: 19453991
215. [Comparison of clinical outcome after autologous stem cell transplantation between patients with peripheral T-cell lymphomas and diffuse large B-cell lymphoma.](#)
Sohn BS, Park I, Kim EK, Yoon DH, Lee SS, Kang BW, Jang G, Choi YH, Kim C, Lee DH, Kim S, Huh J, Suh C.
Bone Marrow Transplant. 2009 Sep;44(5):287-93. doi: 10.1038/bmt.2009.29. Epub 2009 Feb 23.
PMID: 19234508
216. [Epidermal growth factor receptor tyrosine kinase inhibitors as a first-line therapy for never-smokers with adenocarcinoma of the lung having asymptomatic synchronous brain metastasis.](#)
Kim JE, Lee DH, Choi Y, Yoon DH, Kim SW, Suh C, Lee JS.
Lung Cancer. 2009 Sep;65(3):351-4. doi: 10.1016/j.lungcan.2008.12.011. Epub 2009 Jan 20.
PMID: 19157632
217. [Phase II study of erlotinib as a salvage treatment for non-small-cell lung cancer patients after failure of gefitinib treatment.](#)
Lee DH, Kim SW, Suh C, Yoon DH, Yi EJ, Lee JS.
Ann Oncol. 2008 Dec;19(12):2039-42. doi: 10.1093/annonc/mdn423. Epub 2008 Jul 21.
PMID: 18644828 Free PMC article. Clinical Trial.